{"gene":"PTGS2","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":1992,"finding":"Human COX-2 (PTGS2) was cloned from umbilical vein endothelial cells; its cDNA encodes a 604-amino-acid polypeptide 61% identical to COX-1, and expression of the open reading frame in COS-7 cells confers cyclooxygenase activity, demonstrating it is a functional prostaglandin H synthase. COX-2 mRNA was preferentially induced by PMA and LPS in endothelial cells and monocytes.","method":"Molecular cloning, in vitro translation, heterologous expression in COS-7 cells with enzymatic activity assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — reconstitution of enzymatic activity in heterologous cells; foundational cloning paper","pmids":["1380156"],"is_preprint":false},{"year":1993,"finding":"Human PHS II (PTGS2) was independently cloned from an endothelial cell cDNA library; the protein shares 61% identity with PHS I, maps to chromosome 1 (distinct from PHS I on chromosome 9), and its mRNA is induced by TNF, PMA, LPS, and IL-1 in endothelial cells, with induction correlating with increased prostacyclin biosynthesis. Cycloheximide induced mRNA without activity increase, confirming translation is required for functional enzyme.","method":"Molecular cloning, chromosomal mapping (Southern analysis), mRNA induction assays, prostacyclin biosynthesis measurement","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — independent cloning with functional correlation; replicated foundational result","pmids":["8473346"],"is_preprint":false},{"year":1994,"finding":"Structure of the human COX-2 gene (PTGS2) was determined: 10 exons spanning ~8.3 kb, mapped to chromosome 1q25.2-q25.3 (distinct from PTGS1 at 9q32-q33.3). The 5'-flanking region contains a TATA box and regulatory elements including NF-κB, CRE, AP-2, SP1, and Ets-1 sites. The large 3'-UTR exon contains 22 copies of the AUUUA mRNA instability element, indicating post-transcriptional regulation.","method":"Genomic library screening, DNA sequencing, primer extension, fluorescence in situ hybridization (FISH)","journal":"European journal of biochemistry / The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — complete gene structure determination with functional regulatory element identification; two independent reports","pmids":["8181472","7945196"],"is_preprint":false},{"year":1994,"finding":"Recombinant human PTGS2 (PGHS-2) expressed in a baculovirus system possesses both cyclooxygenase and peroxidase activities, has high affinity for arachidonate as substrate, and undergoes self-inactivation during catalysis. The enzyme is glycosylated with heterogeneous glycosylation, and certain NSAIDs selectively inhibit PGHS-2 over PGHS-1.","method":"Baculovirus expression, enzyme purification, kinetic assays (cyclooxygenase and peroxidase activities), SDS-PAGE, N-terminal sequencing","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 — purified recombinant enzyme with in vitro activity characterization and kinetics","pmids":["7947975"],"is_preprint":false},{"year":1994,"finding":"COX-2 protein is constitutively expressed at a basal level in granulomatous tissue during the chronic phase of murine inflammation, and COX-2 protein rises progressively during inflammation peaking at day 14, while COX-1 protein remains unaltered throughout—establishing distinct regulatory behavior for the two isoforms in vivo.","method":"Western blot, enzymatic activity assay in murine air-pouch granuloma model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — direct protein quantification with functional readout in defined in vivo inflammatory model","pmids":["7510883"],"is_preprint":false},{"year":1998,"finding":"PTGS2 (COX-2) subcellular localization was determined by immunoelectron microscopy: both PGHS-1 and PGHS-2 reside on the lumenal surfaces of the endoplasmic reticulum and nuclear envelope (inner and outer nuclear membranes) in human monocytes, NIH 3T3 cells, and HUVECs. Subcellular fractionation and isozyme-specific inhibitor studies confirm similar distribution and product profiles, indicating independent functioning is not attributable to different subcellular compartments.","method":"Immunoelectron microscopy, subcellular fractionation, Western blotting, isozyme-selective inhibitor product analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — high-resolution localization with orthogonal biochemical validation across multiple cell types","pmids":["9545330"],"is_preprint":false},{"year":1998,"finding":"COX-2-overexpressing colon carcinoma cells stimulate endothelial cell migration and tube formation (angiogenesis) through production of prostaglandins and proangiogenic factors; selective COX-2 inhibitor NS-398 blocks this effect. COX-1 in endothelial cells also regulates angiogenesis independently, as shown by COX-1 antisense inhibition of tube formation, establishing a dual-mechanism model for cyclooxygenase regulation of tumor angiogenesis.","method":"In vitro coculture angiogenesis assay, COX-2 overexpression, NS-398 inhibition, neutralizing antibodies to angiogenic factors, COX-1 antisense oligonucleotides","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — mechanistic cell-based assays with genetic and pharmacological perturbation; highly cited foundational paper","pmids":["9630216"],"is_preprint":false},{"year":1997,"finding":"In adult human kidney, COX-2 immunoreactivity localizes to endothelial and smooth muscle cells of arteries and veins and to intraglomerular podocytes (not macula densa, unlike rat), suggesting a primary role in regulation of renal perfusion and glomerular hemodynamics. In fetal kidney, COX-2 appears in podocytes only at the end-stage of renal development.","method":"Immunohistology, in situ mRNA hybridization with digoxigenin-labeled riboprobes","journal":"The American journal of physiology","confidence":"High","confidence_rationale":"Tier 2 — direct localization by two independent methods with species-specific and developmental resolution","pmids":["9140046"],"is_preprint":false},{"year":2002,"finding":"Aspirin acetylates COX-2, switching its oxygenation of DHA from 13-HDHA to 17R-HDHA; human COX-2 converts DHA to 13-hydroxy-DHA which is redirected by aspirin-acetylation to 17R-HDHA, the precursor of anti-inflammatory resolvins. This demonstrates that aspirin-acetylated COX-2 retains oxygenase activity but with altered stereospecificity, enabling biosynthesis of pro-resolution lipid mediators.","method":"Lipidomic analysis (LC-MS), in vitro enzyme assays with aspirin-treated human COX-2, isotope labeling, cell-based experiments with human microglial and endothelial cells","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — mechanistic in vitro enzyme assay with product characterization and functional validation; seminal resolvin discovery paper","pmids":["12391014"],"is_preprint":false},{"year":2002,"finding":"A common COX-2 promoter variant (-765G>C) significantly reduces promoter activity (~28-31% lower) in human lung fibroblasts basally and in serum-stimulated conditions. Carriers of the -765C allele show lower post-operative CRP elevation after coronary bypass surgery, linking reduced PTGS2 promoter activity to attenuated acute-phase inflammatory response in vivo.","method":"Reporter gene assay, PCR-based variant screening, clinical association study with plasma CRP measurement","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 2 — functional promoter assay replicated by clinical phenotype correlation","pmids":["12377741"],"is_preprint":false},{"year":2003,"finding":"Membrane-bound prostaglandin E synthase-2 (mPGES-2), while constitutively expressed, promotes PGE2 production via both COX-1 and COX-2 with modest COX-2 preference, in contrast to mPGES-1 which preferentially couples to COX-2. This establishes that PTGS2 (COX-2) can functionally couple with multiple downstream prostaglandin synthases.","method":"Cell-based overexpression, isozyme-selective inhibitor studies, PGE2 measurement by immunoassay, subcellular fractionation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — functional coupling demonstrated in multiple cell lines with orthogonal methods","pmids":["12835322"],"is_preprint":false},{"year":2005,"finding":"Inducible nitric oxide synthase (iNOS) physically binds to COX-2 (PTGS2) and S-nitrosylates it, enhancing COX-2 catalytic activity. Selectively disrupting the iNOS–COX-2 binding interaction prevents NO-mediated activation of COX-2, establishing a direct protein–protein interaction that amplifies inflammatory signaling.","method":"Co-immunoprecipitation, S-nitrosylation assay, selective disruption of protein-protein interaction, in vitro activity assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 1–2 — direct binding demonstrated by Co-IP with functional consequence via activity assay and disruption experiment","pmids":["16373578"],"is_preprint":false},{"year":2005,"finding":"miR-16, containing a sequence complementary to the AU-rich element (ARE) in the COX-2 3'-UTR, is required for ARE-mediated mRNA turnover of COX-2 mRNA. miR-16 works in concert with the ARE-binding protein tristetraprolin (TTP) through association with Ago/eiF2C family members to target ARE-containing mRNAs for degradation, establishing a microRNA-dependent mechanism for post-transcriptional regulation of PTGS2.","method":"RNAi screen in Drosophila S2 cells, siRNA knockdown in HeLa cells, mRNA stability assays, sequence-specificity controls","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — mechanistic finding replicated across species with sequence-specific controls and protein interaction evidence","pmids":["15766526"],"is_preprint":false},{"year":2006,"finding":"TLR4 signaling via MyD88 is required for optimal Cox-2 expression in intestinal epithelial cells; LPS-mediated PGE2 production is blocked by Cox-2 inhibition or siRNA against MyD88. TLR4-deficient mice show reduced proliferation and increased apoptosis after DSS injury, which is rescued by exogenous PGE2, establishing that PTGS2-derived PGE2 downstream of TLR4 is essential for intestinal epithelial repair, potentially through transactivation of the EGF receptor.","method":"Reporter luciferase assay, siRNA knockdown, immunohistochemistry, Western blotting, BrdU/TUNEL assays in TLR4-/- mice, PGE2 rescue experiments","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in vivo combined with pharmacological and siRNA evidence; multiple orthogonal readouts","pmids":["16952555"],"is_preprint":false},{"year":2007,"finding":"COX-2 (PTGS2), together with epiregulin and matrix metalloproteinases 1 and 2, facilitates assembly of new tumor blood vessels, release of tumor cells into circulation, and breaching of lung capillaries to seed pulmonary metastasis from breast cancer cells. Genetic and pharmacological approaches in human breast cancer cells and xenograft models established COX2 as a mediator of vascular remodeling co-opted for lung metastasis.","method":"Genetic perturbation (shRNA knockdown), pharmacological inhibition, xenograft mouse models, in vitro vascular permeability and angiogenesis assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — combined genetic and pharmacological epistasis with defined in vivo metastatic phenotype readout","pmids":["17429393"],"is_preprint":false},{"year":2010,"finding":"COX-2 is a downstream effector of β-adrenergic signaling in white adipose tissue (WAT) and is required for induction of brown adipose tissue (BAT) in WAT depots. Prostaglandins produced by COX-2 shift differentiation of mesenchymal progenitors toward a brown adipocyte phenotype. COX-2 overexpression in WAT induced de novo BAT recruitment, increased systemic energy expenditure, and protected mice against diet-induced obesity.","method":"Cox-2 transgenic mouse model (WAT-specific overexpression), Cox-2 genetic deletion, mesenchymal progenitor differentiation assays, metabolic phenotyping","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — gain- and loss-of-function genetic mouse models with mechanistic cell differentiation assay","pmids":["20448152"],"is_preprint":false},{"year":2010,"finding":"Increasing matrix stiffness across the pathophysiological range strongly suppresses fibroblast COX-2 expression and PGE2 synthesis. Exogenous PGE2 or EP2 receptor agonist completely counteracts the proliferative and matrix-synthetic effects of increased stiffness, establishing an autocrine feedback loop in which COX-2-derived PGE2 maintains fibroblast quiescence and its suppression by matrix stiffening amplifies progressive fibrosis.","method":"Polyacrylamide gel matrix stiffness manipulation, COX-2 mRNA/protein measurement, PGE2 ELISA, pharmacological rescue with exogenous PGE2/EP2 agonist, proliferation and collagen synthesis assays","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — mechanistic pathway defined with pharmacological rescue confirming COX-2/PGE2 as central mediator","pmids":["20733059"],"is_preprint":false},{"year":2011,"finding":"A positive feedback loop between PGE2 and COX-2 redirects monocyte differentiation from CD1a+ dendritic cells to CD14+CD33+CD34+ myeloid-derived suppressor cells (MDSCs). Exogenous PGE2 or diverse COX-2 activators (LPS, IL-1β, IFNγ) induce COX-2 expression and endogenous PGE2 production, driving MDSC-associated suppressive factors. Disruption of COX2-PGE2 feedback using COX2 inhibitors or EP2/EP4 antagonists suppresses MDSC function.","method":"Monocyte differentiation assays, flow cytometry, pharmacological inhibition (COX2 inhibitors, EP2/EP4 antagonists), ovarian cancer patient samples","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — autocrine feedback mechanism demonstrated with pharmacological dissection and clinical validation in cancer specimens","pmids":["21972293"],"is_preprint":false},{"year":2014,"finding":"The non-receptor tyrosine kinase FYN physically interacts with COX-2 (PTGS2) and phosphorylates it at Tyr446; a phospho-mimetic mutation at Tyr446 promotes COX-2 activity, while a phosphorylation-blocking mutation prevents FYN-mediated activity increase, establishing post-translational regulation of COX-2 enzymatic activity by tyrosine phosphorylation independent of changes in protein expression.","method":"Co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis (phospho-mimetic and blocking mutants), COX-2 activity assays in prostate cancer cells","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 1–2 — direct phosphorylation demonstrated with mutagenesis confirming functional consequence on enzymatic activity","pmids":["24970799"],"is_preprint":false},{"year":2015,"finding":"DNA methylation at the PTGS2 CpG island disrupts CTCF/cohesin complex binding, abrogating chromatin loop formation at the PTGS2 locus and reducing enrichment of positive elongation factor b at the transcriptional start site, thereby downregulating PTGS2 expression. Demethylation restores CTCF/cohesin binding and chromatin looping, re-activating PTGS2 transcription.","method":"Chromatin immunoprecipitation (ChIP), chromatin conformation capture (3C), bisulfite sequencing, demethylation treatment, CTCF/cohesin knockdown","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — mechanistic epigenetic regulation defined through multiple chromatin biology methods with functional gene expression readout","pmids":["25703332"],"is_preprint":false},{"year":2015,"finding":"Ku80 binds the COX-2 (PTGS2) gene promoter and upregulates COX-2 expression in lung cancer cells; the transcriptional co-activator CBP interacts with Ku80 and acetylates it, promoting COX-2 promoter activation. Ku80 knockdown suppresses COX-2 expression, inhibits ERK phosphorylation, and impairs tumor growth in vivo.","method":"Streptavidin-agarose promoter pulldown with proteomics, Co-IP, siRNA knockdown, reporter assays, xenograft mouse model","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2–3 — promoter binding confirmed by pulldown/proteomics with functional in vivo validation; single lab","pmids":["25797267"],"is_preprint":false},{"year":2015,"finding":"The transcription factor ATF3 negatively regulates Ptgs2 expression by binding to the Ptgs2 promoter in activated macrophages. In Atf3-/- mice, peritoneal macrophages show higher Ptgs2 expression and prostaglandin production after zymosan stimulation, and acute peritonitis shows increased leukocyte accumulation and PGE2/PGD2 levels, establishing ATF3 as a transcriptional repressor that terminates Ptgs2 expression during acute inflammation.","method":"Chromatin immunoprecipitation (ChIP), Atf3-/- mouse model, RT-PCR, ELISA for prostaglandins, peritonitis model","journal":"Prostaglandins & other lipid mediators","confidence":"High","confidence_rationale":"Tier 2 — direct promoter binding by ChIP validated in genetic KO model with in vivo inflammatory phenotype","pmids":["25619459"],"is_preprint":false},{"year":2019,"finding":"EPHA2 signaling through TGFβ promotes PTGS2 expression in pancreatic tumor cells; Epha2 or Ptgs2 deletion each reverses T cell exclusion from the tumor microenvironment and sensitizes tumors to immunotherapy, placing PTGS2 downstream of EPHA2-TGFβ in a pathway that drives immunosuppression.","method":"Genetic deletion (Epha2-/- and Ptgs2-/- mouse models), pharmacological PTGS2 inhibition, tumor immunophenotyping, immunotherapy response assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis confirmed with two independent KO models and pharmacological validation with defined immune phenotype","pmids":["31162144"],"is_preprint":false},{"year":2019,"finding":"Cisplatin induces PTGS2 expression through ROS/NF-κB pathway; PTGS2 then mediates resistance to apoptosis via PGE2/EP4/MAPKs (ERK1/2, P38) axis, upregulating BCL2. Inhibition of PTGS2 by celecoxib augments cisplatin cytotoxicity in resistant gastric cancer cells and xenografts through suppression of PTGS2 and BCL2.","method":"Western blotting, ROS measurement, NF-κB pathway inhibitors, PGE2/EP4 axis interrogation, xenograft mouse model, clinical specimen correlation","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2–3 — pathway placement by pharmacological dissection with in vivo validation; single lab","pmids":["31518663"],"is_preprint":false},{"year":2019,"finding":"Inhibition of mitochondrial oxidative phosphorylation activates AMPK, which stabilizes Ptgs2 mRNA post-transcriptionally in astrocytes, leading to increased COX-2 protein and enhanced eicosanoid secretion (PGE2, PGF2α, 6-keto-PGF1α). AMPK silencing prevents Ptgs2 upregulation by mitochondrial inhibitors, while AMPK activators recapitulate Ptgs2 mRNA stabilization.","method":"Mitochondrial inhibitors, AMPK siRNA knockdown, AMPK activators, mRNA stability assay, LC/MS eicosanoid profiling","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 — AMPK-dependent mRNA stabilization confirmed by both loss- and gain-of-function; single lab","pmids":["31581537"],"is_preprint":false},{"year":2021,"finding":"Macrophage COX-2 is required for efferocytosis (phagocytosis of apoptotic neutrophils) and efferocytosis-dependent macrophage reprogramming. Loss of Cox2 impairs macrophage binding capacity for apoptotic cells, dysregulates polarization, and inhibits production of pro-resolution eicosanoids (PGI2, PGE2, lipoxin A4, 15d-PGJ2). COX2-competent efferocytic macrophages induce intestinal epithelial organoid restitution and repair.","method":"Macrophage-specific Cox2 knockout, pharmacological COX2 inhibition, efferocytosis assays with apoptotic neutrophils and synthetic targets, LC-MS/MS eicosanoid lipidomics, intestinal organoid co-culture","journal":"Cellular and molecular gastroenterology and hepatology","confidence":"High","confidence_rationale":"Tier 2 — genetic KO combined with lipidomic profiling and organoid functional assay with multiple orthogonal methods","pmids":["35017061"],"is_preprint":false},{"year":2021,"finding":"During RAS-induced senescence, COX2 regulates SASP composition through an autocrine feedback loop: COX2-derived PGE2 binds EP4 to modulate expression of multiple inflammatory SASP components including CXCL1. In vivo, Cox2 is required for hepatocyte senescence surveillance, NK/T cell-mediated clearance of senescent cells, and tumor suppression; loss of Cox2 enriches immunosuppressive immature myeloid cells and Treg lymphocytes in the intrahepatic immune microenvironment.","method":"RAS-induced senescence model, Cox2 genetic deletion, in vivo hepatocyte senescence model, immune cell profiling, SASP cytokine measurement, PGE2/EP4 pathway pharmacology","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with mechanistic autocrine loop dissection and in vivo immune phenotype; multiple orthogonal methods","pmids":["33730589"],"is_preprint":false},{"year":2022,"finding":"The transcription factor CTCF, together with the lncRNA PACERR, recruits the histone acetyltransferase p300 to the promoter regions of PTGS2, enhancing histone acetylation and increasing PTGS2 transcription in tumor-associated macrophages. This CTCF/PACERR/p300 complex promotes M2-like macrophage polarization in pancreatic ductal adenocarcinoma.","method":"RNA-seq, ATAC-seq, ChIP-seq, RNA immunoprecipitation, RNA pulldown, CTCF/PACERR knockdown with lentivirus, in vitro and in vivo functional assays","journal":"Clinical and translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 — multi-omics with direct RNA-protein interaction validated by RIP and pulldown; single lab","pmids":["35184402"],"is_preprint":false},{"year":2022,"finding":"DCLK1 kinase binds and phosphorylates XRCC5 (Ku80), which then transcriptionally activates COX-2 (PTGS2) expression and enhances PGE2 production, generating an inflammatory tumor microenvironment that promotes colorectal cancer aggressiveness and stemness.","method":"Proteomics, Co-IP, in vitro kinase assay, DCLK1 kinase inhibition in CRC mouse models, gene expression analysis","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 — direct phosphorylation by kinase assay with downstream COX-2 activation validated in mouse models; single lab","pmids":["35910805"],"is_preprint":false},{"year":2024,"finding":"Endothelial ROBO4 suppresses PTGS2/COX-2 expression by interacting with IQGAP1 and the ubiquitin E3 ligase TRAF7; ROBO4 enhances TRAF7-mediated ubiquitination of IQGAP1, inhibiting prolonged RAC1 activation and thereby decreasing PTGS2 expression in inflammatory endothelial cells. Robo4-deficient mice show exacerbated PTGS2-associated inflammatory diseases (arthritis, edema, pain).","method":"RNA-seq, Co-IP (ROBO4-IQGAP1-TRAF7 interaction), ubiquitination assay, RAC1 activation assay, Robo4-/- mouse model with inflammatory disease phenotyping","journal":"Communications biology","confidence":"High","confidence_rationale":"Tier 2 — mechanistic protein complex defined by Co-IP with ubiquitination assay and validated in KO mouse with disease readout","pmids":["38762541"],"is_preprint":false},{"year":2016,"finding":"A small but significant amount of COX-2 protein and mRNA is constitutively expressed in human platelets; the COX1/COX2 mRNA ratio in platelets is ~370:1 and protein ratio ~17:1. COX-2 is also present in platelet-derived microparticles, suggesting a role for platelet COX-2 in physiological and pathological processes including thrombosis.","method":"Quantitative RT-PCR, immunostaining, Western blotting of isolated platelets and platelet-derived microparticles","journal":"Platelets","confidence":"Medium","confidence_rationale":"Tier 2 — direct protein and mRNA detection with quantitative methods; functional role inferred","pmids":["27534811"],"is_preprint":false},{"year":2022,"finding":"The transcription factor HIF1α binds to the promoter of Ptgs2 and upregulates its expression; atorvastatin inhibits the HIF1α/Ptgs2 axis, attenuating Ptgs2-mediated ferroptosis and inflammation following coronary microembolization in rats, as confirmed by chromatin immunoprecipitation demonstrating direct HIF1α binding to the Ptgs2 promoter.","method":"Chromatin immunoprecipitation (ChIP), Ptgs2 silencing, rat CME model, ferroptosis marker quantification (MDA, GSH, Fe2+), cardiac function assessment","journal":"Frontiers in pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP demonstrates direct transcription factor-promoter interaction with functional in vivo validation; single lab","pmids":["36569299"],"is_preprint":false},{"year":2016,"finding":"Activin A upregulates PTGS2 expression and increases PGE2 production in human granulosa-lutein cells via an ACVR1B-mediated SMAD2/3-SMAD4 signaling pathway, as demonstrated by TGF-β/activin receptor inhibition and SMAD-specific siRNA knockdown.","method":"Receptor inhibitor (SB431542), siRNA knockdown of SMADs, PTGS2 mRNA/protein measurement, PGE2 ELISA in primary and immortalized human granulosa-lutein cells","journal":"Reproduction","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological and genetic dissection of signaling pathway with functional PGE2 readout; single lab","pmids":["27624482"],"is_preprint":false},{"year":2022,"finding":"LRH-1/NR5A2 regulates PTGS2/COX-2 expression in pancreatic beta cells; LRH-1 ablation blunts Ptgs2 induction by the LRH-1 agonist BL001. Ptgs2 inactivation reduces PGE2 levels and abrogates BL001-mediated islet survival (increased cytochrome c release and cleaved PARP). The PTGER1 receptor antagonist negates BL001-mediated islet survival, defining the LRH-1/PTGS2/PGE2/PTGER1 signaling axis as a beta cell survival pathway.","method":"Conditional beta-cell-specific LRH-1 knockout, Ptgs2 inactivation, PGE2 measurement, cytochrome c release and PARP cleavage assays, EP receptor pharmacology","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 — genetic pathway defined with conditional KO and pharmacological receptor dissection; single lab","pmids":["35602948"],"is_preprint":false}],"current_model":"PTGS2/COX-2 is an inducible prostaglandin endoperoxide H synthase localized to the lumenal face of the ER and nuclear envelope that catalyzes the committed step—conversion of arachidonic acid to PGH2—using both cyclooxygenase and peroxidase activities; its enzymatic output is amplified post-translationally by iNOS-mediated S-nitrosylation and FYN-mediated Tyr446 phosphorylation, and is suppressed at the transcriptional level by ATF3 binding to its promoter, by CTCF/cohesin-mediated chromatin looping (disrupted by DNA methylation), and by the ROBO4-IQGAP1-TRAF7-RAC1 endothelial axis; upstream, PTGS2 is induced downstream of TLR4-MyD88, EPHA2-TGFβ, LRH-1, HIF1α, activin A-SMAD2/3, Gq-calcineurin, and DCLK1-XRCC5 pathways, while aspirin-acetylated COX-2 retains oxygenase activity with altered stereospecificity to generate resolvin precursors; the PGE2 it produces forms autocrine feedback loops that regulate SASP composition during senescence surveillance, redirect monocyte differentiation toward MDSCs, maintain fibroblast quiescence via EP2, and support intestinal epithelial repair and beta-cell survival via PTGER1."},"narrative":{"teleology":[{"year":1992,"claim":"Cloning of human PTGS2 from endothelial cells and demonstration of cyclooxygenase activity in heterologous cells established it as a second, inducible prostaglandin H synthase isoform distinct from COX-1, answering whether a separate inducible cyclooxygenase gene exists in humans.","evidence":"Molecular cloning from HUVECs with functional expression in COS-7 cells; independently replicated with chromosomal mapping to 1q25","pmids":["1380156","8473346"],"confidence":"High","gaps":["Crystal structure of human COX-2 not yet solved at this time","Substrate specificity differences versus COX-1 not yet characterized","In vivo physiological roles undefined"]},{"year":1994,"claim":"Determination of the PTGS2 gene structure revealed ARE-rich 3'-UTR elements and NF-κB/CRE promoter sites, explaining how COX-2 is both transcriptionally induced and post-transcriptionally labile; concurrent biochemical characterization of recombinant enzyme confirmed dual cyclooxygenase and peroxidase activities with self-inactivation kinetics.","evidence":"Genomic sequencing with FISH mapping; baculovirus-expressed purified enzyme with kinetic analysis","pmids":["8181472","7945196","7947975"],"confidence":"High","gaps":["Identity of trans-acting factors for ARE-mediated decay unknown","Structural basis for NSAID selectivity not resolved","Post-translational regulatory mechanisms uncharacterized"]},{"year":1998,"claim":"Immunoelectron microscopy resolved the long-standing question of whether COX-1 and COX-2 occupy distinct compartments: both localize to the ER and nuclear envelope lumen, indicating their functional independence arises from differential expression rather than compartmentalization.","evidence":"Immunogold EM across monocytes, NIH 3T3, and HUVECs with subcellular fractionation and isozyme-selective inhibitor controls","pmids":["9545330"],"confidence":"High","gaps":["Mechanism of preferential coupling to specific downstream synthases despite shared localization unclear","Whether nuclear envelope localization has distinct functional consequences unknown"]},{"year":1998,"claim":"Demonstration that COX-2-overexpressing tumor cells stimulate angiogenesis through prostaglandin production established COX-2 as a pro-tumorigenic enzyme, shifting the field beyond inflammation to cancer biology.","evidence":"Coculture angiogenesis assays with COX-2 overexpression and NS-398 inhibition in colon carcinoma and endothelial cells","pmids":["9630216"],"confidence":"High","gaps":["Specific prostaglandin species mediating angiogenesis not fully defined","In vivo relevance to spontaneous tumor angiogenesis not yet shown"]},{"year":2002,"claim":"Discovery that aspirin-acetylated COX-2 retains oxygenase activity but with altered stereospecificity to produce 17R-HDHA (resolvin precursor) from DHA revealed an unexpected gain-of-function mechanism, redefining aspirin's anti-inflammatory action beyond simple enzyme inhibition.","evidence":"LC-MS lipidomic analysis of aspirin-treated recombinant COX-2 with cell-based validation in microglia and endothelial cells","pmids":["12391014"],"confidence":"High","gaps":["Quantitative contribution of aspirin-triggered resolvins to clinical anti-inflammatory effects not established","Whether other COX-2 covalent modifications similarly redirect stereospecificity unknown"]},{"year":2005,"claim":"Two post-transcriptional and post-translational control layers were defined: miR-16 cooperates with tristetraprolin to degrade COX-2 mRNA via its ARE, and iNOS physically binds and S-nitrosylates COX-2 to enhance its catalytic activity, establishing that COX-2 output is regulated beyond transcription.","evidence":"miR-16 RNAi screen in Drosophila S2 validated in HeLa; iNOS–COX-2 Co-IP with S-nitrosylation assay and interaction disruption","pmids":["15766526","16373578"],"confidence":"High","gaps":["S-nitrosylation site(s) on COX-2 not mapped","Whether miR-16 and S-nitrosylation operate simultaneously in the same cell types unclear"]},{"year":2006,"claim":"Genetic studies in TLR4-deficient mice placed PTGS2-derived PGE2 downstream of TLR4-MyD88 in intestinal epithelial repair, explaining how innate immune sensing drives mucosal homeostasis through prostanoid production.","evidence":"TLR4−/− mice with DSS colitis, MyD88 siRNA, BrdU/TUNEL assays, PGE2 rescue","pmids":["16952555"],"confidence":"High","gaps":["EP receptor subtype mediating intestinal repair downstream of TLR4 not fully defined","Whether epithelial or stromal COX-2 is the principal source not resolved"]},{"year":2010,"claim":"COX-2 was identified as an effector of β-adrenergic signaling that drives brown adipocyte recruitment in white fat depots, and separately as a mechanoresponsive gene whose suppression by matrix stiffening removes the PGE2/EP2 brake on fibroblast activation, broadening COX-2 biology to metabolism and fibrosis.","evidence":"WAT-specific Cox-2 transgenic and knockout mice with metabolic phenotyping; tunable-stiffness polyacrylamide gels with PGE2/EP2 rescue in fibroblasts","pmids":["20448152","20733059"],"confidence":"High","gaps":["Identity of the prostaglandin species mediating brown fat induction not fully resolved","In vivo relevance of matrix-stiffness–COX-2 axis in human fibrotic disease not confirmed"]},{"year":2011,"claim":"A COX-2/PGE2 autocrine feedback loop was shown to redirect monocyte differentiation toward immunosuppressive MDSCs via EP2/EP4, providing a mechanistic link between tumor-derived COX-2 activity and immune evasion.","evidence":"Monocyte differentiation assays with COX-2 inhibitors and EP2/EP4 antagonists; validated in ovarian cancer patient specimens","pmids":["21972293"],"confidence":"High","gaps":["Whether this loop operates in all tumor types or is context-specific unclear","Downstream transcriptional program in MDSCs not fully mapped"]},{"year":2014,"claim":"FYN-mediated phosphorylation of COX-2 at Tyr446 was identified as a post-translational activating modification, establishing that kinase signaling directly modulates COX-2 enzymatic output independent of expression changes.","evidence":"Co-IP, in vitro kinase assay, phospho-mimetic and blocking mutants in prostate cancer cells","pmids":["24970799"],"confidence":"High","gaps":["Whether Tyr446 phosphorylation occurs in non-cancer contexts unknown","Phosphatase(s) that reverse this modification not identified"]},{"year":2015,"claim":"Epigenetic and transcriptional silencing mechanisms were defined: DNA methylation at the PTGS2 CpG island disrupts CTCF/cohesin-mediated chromatin looping, while ATF3 directly represses the Ptgs2 promoter during inflammation resolution, establishing how PTGS2 is turned off.","evidence":"ChIP, 3C chromatin conformation capture, bisulfite sequencing, demethylation; Atf3−/− mice with peritonitis model and ChIP","pmids":["25703332","25619459"],"confidence":"High","gaps":["Whether CTCF/cohesin and ATF3 mechanisms operate sequentially or independently unresolved","Writers responsible for PTGS2 CpG island methylation not identified"]},{"year":2019,"claim":"EPHA2-TGFβ signaling was placed upstream of PTGS2 in pancreatic cancer immune evasion, and AMPK-dependent mRNA stabilization was identified as a metabolic stress–responsive post-transcriptional mechanism, further expanding the repertoire of PTGS2 induction pathways.","evidence":"Epha2−/− and Ptgs2−/− mouse tumor models with immunotherapy; AMPK siRNA and activators with mRNA stability assays in astrocytes","pmids":["31162144","31581537"],"confidence":"High","gaps":["AMPK-dependent stabilization mechanism (RNA-binding protein intermediary) not identified","Whether EPHA2-PTGS2 axis is specific to pancreatic cancer or generalizable unclear"]},{"year":2021,"claim":"COX-2 was shown to be essential for macrophage efferocytosis and subsequent pro-resolution reprogramming, and for shaping SASP composition during senescence surveillance via PGE2/EP4 autocrine signaling, revealing COX-2 as a gatekeeper of immune resolution programs.","evidence":"Macrophage-specific Cox2 KO with efferocytosis assays and LC-MS/MS lipidomics; RAS-induced senescence with Cox2 deletion and in vivo hepatocyte surveillance model","pmids":["35017061","33730589"],"confidence":"High","gaps":["Molecular mechanism by which COX-2 loss impairs apoptotic cell binding not defined","Whether senescence surveillance role extends beyond hepatocytes unknown"]},{"year":2022,"claim":"Multiple transcriptional activators of PTGS2 were further defined: CTCF/PACERR/p300 complex in tumor-associated macrophages, DCLK1-phosphorylated Ku80 in colorectal cancer, HIF1α direct promoter binding in cardiac ischemia, and LRH-1 in beta cells, revealing tissue-specific transcriptional wiring converging on PTGS2.","evidence":"ChIP-seq, RNA pulldown, RIP for CTCF/PACERR; DCLK1 kinase assay with Co-IP; HIF1α ChIP in rat CME model; conditional beta-cell LRH-1 KO with EP receptor pharmacology","pmids":["35184402","35910805","36569299","35602948"],"confidence":"Medium","gaps":["Whether PACERR lncRNA is required or modulatory for PTGS2 induction needs independent replication","DCLK1-Ku80-COX-2 axis demonstrated in single lab","HIF1α-PTGS2-ferroptosis link requires human validation"]},{"year":2024,"claim":"An endothelial-specific suppressive pathway was delineated: ROBO4 recruits TRAF7 to ubiquitinate IQGAP1, preventing sustained RAC1 activation and thereby suppressing PTGS2 expression, with Robo4-deficient mice exhibiting exacerbated inflammatory disease.","evidence":"Co-IP of ROBO4-IQGAP1-TRAF7, ubiquitination assay, RAC1 activation assay, Robo4−/− mice with arthritis/edema/pain models","pmids":["38762541"],"confidence":"High","gaps":["Whether ROBO4-TRAF7 axis operates in non-endothelial cell types unknown","Direct ligand triggering ROBO4 to suppress COX-2 not defined"]},{"year":null,"claim":"Unresolved questions include: the structural basis for how S-nitrosylation and Tyr446 phosphorylation individually and combinatorially alter COX-2 catalytic geometry; the mechanism by which COX-2 preferentially couples to mPGES-1 despite shared ER localization with COX-1; and whether COX-2's roles in efferocytosis, senescence surveillance, and brown fat recruitment depend on the same or distinct prostaglandin products.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal structure of S-nitrosylated or Tyr446-phosphorylated COX-2","Prostaglandin species specificity for individual tissue-level functions not resolved","Mechanistic basis for preferential COX-2–mPGES-1 coupling still debated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,1,3,8]},{"term_id":"GO:0009975","term_label":"cyclase activity","supporting_discovery_ids":[0,3]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[5]},{"term_id":"GO:0005635","term_label":"nuclear envelope","supporting_discovery_ids":[5]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,3,8,10,15]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,13,17,22,25,26]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[13,16,22,29,32,33]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[6,14,22,23]}],"complexes":[],"partners":["NOS2","FYN","ATF3","CTCF","XRCC5","IQGAP1","TRAF7"],"other_free_text":[]},"mechanistic_narrative":"PTGS2 (COX-2) is an inducible bifunctional enzyme that catalyzes the committed step in prostanoid biosynthesis—converting arachidonic acid to PGH2 via sequential cyclooxygenase and peroxidase activities—and resides on the lumenal face of the endoplasmic reticulum and nuclear envelope [PMID:1380156, PMID:7947975, PMID:9545330]. Transcriptional induction is driven by NF-κB, HIF1α, LRH-1, SMAD2/3, and CTCF/cohesin-dependent chromatin looping, while ATF3 acts as a transcriptional repressor; post-transcriptionally, miR-16 promotes ARE-mediated mRNA decay and AMPK stabilizes PTGS2 mRNA [PMID:25619459, PMID:25703332, PMID:15766526, PMID:31581537]. Enzymatic output is amplified by iNOS-mediated S-nitrosylation and FYN-dependent Tyr446 phosphorylation, and aspirin acetylation redirects oxygenase stereospecificity to generate pro-resolution resolvin precursors from DHA [PMID:16373578, PMID:24970799, PMID:12391014]. The PGE2 produced by PTGS2 drives diverse tissue-specific programs including intestinal epithelial repair downstream of TLR4, senescence surveillance via autocrine EP4 signaling, monocyte-to-MDSC differentiation, brown adipocyte recruitment in white fat, macrophage efferocytosis, and tumor immune evasion downstream of EPHA2-TGFβ [PMID:16952555, PMID:33730589, PMID:21972293, PMID:20448152, PMID:35017061, PMID:31162144]."},"prefetch_data":{"uniprot":{"accession":"P35354","full_name":"Prostaglandin G/H synthase 2","aliases":["Cyclooxygenase-2","COX-2","PHS II","Prostaglandin H2 synthase 2","PGH synthase 2","PGHS-2","Prostaglandin-endoperoxide synthase 2"],"length_aa":604,"mass_kda":69.0,"function":"Dual cyclooxygenase and peroxidase in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory response (PubMed:11939906, PubMed:16373578, PubMed:19540099, PubMed:22942274, PubMed:26859324, PubMed:27226593, PubMed:7592599, PubMed:7947975, PubMed:9261177). The cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the hydroxy endoperoxide prostaglandin H2 (PGH2), the precursor of all 2-series prostaglandins and thromboxanes (PubMed:16373578, PubMed:22942274, PubMed:26859324, PubMed:27226593, PubMed:7592599, PubMed:7947975, PubMed:9261177). This complex transformation is initiated by abstraction of hydrogen at carbon 13 (with S-stereochemistry), followed by insertion of molecular O2 to form the endoperoxide bridge between carbon 9 and 11 that defines prostaglandins. The insertion of a second molecule of O2 (bis-oxygenase activity) yields a hydroperoxy group in PGG2 that is then reduced to PGH2 by two electrons (PubMed:16373578, PubMed:22942274, PubMed:26859324, PubMed:27226593, PubMed:7592599, PubMed:7947975, PubMed:9261177). Similarly catalyzes successive cyclooxygenation and peroxidation of dihomo-gamma-linoleate (DGLA, C20:3(n-6)) and eicosapentaenoate (EPA, C20:5(n-3)) to corresponding PGH1 and PGH3, the precursors of 1- and 3-series prostaglandins (PubMed:11939906, PubMed:19540099). In an alternative pathway of prostanoid biosynthesis, converts 2-arachidonoyl lysophopholipids to prostanoid lysophopholipids, which are then hydrolyzed by intracellular phospholipases to release free prostanoids (PubMed:27642067). Metabolizes 2-arachidonoyl glycerol yielding the glyceryl ester of PGH2, a process that can contribute to pain response (PubMed:22942274). Generates lipid mediators from n-3 and n-6 polyunsaturated fatty acids (PUFAs) via a lipoxygenase-type mechanism. Oxygenates PUFAs to hydroperoxy compounds and then reduces them to corresponding alcohols (PubMed:11034610, PubMed:11192938, PubMed:9048568, PubMed:9261177). Plays a role in the generation of resolution phase interaction products (resolvins) during both sterile and infectious inflammation (PubMed:12391014). Metabolizes docosahexaenoate (DHA, C22:6(n-3)) to 17R-HDHA, a precursor of the D-series resolvins (RvDs) (PubMed:12391014). As a component of the biosynthetic pathway of E-series resolvins (RvEs), converts eicosapentaenoate (EPA, C20:5(n-3)) primarily to 18S-HEPE that is further metabolized by ALOX5 and LTA4H to generate 18S-RvE1 and 18S-RvE2 (PubMed:21206090). In vascular endothelial cells, converts docosapentaenoate (DPA, C22:5(n-3)) to 13R-HDPA, a precursor for 13-series resolvins (RvTs) shown to activate macrophage phagocytosis during bacterial infection (PubMed:26236990). In activated leukocytes, contributes to oxygenation of hydroxyeicosatetraenoates (HETE) to diHETES (5,15-diHETE and 5,11-diHETE) (PubMed:22068350, PubMed:26282205). Can also use linoleate (LA, (9Z,12Z)-octadecadienoate, C18:2(n-6)) as substrate and produce hydroxyoctadecadienoates (HODEs) in a regio- and stereospecific manner, being (9R)-HODE ((9R)-hydroxy-(10E,12Z)-octadecadienoate) and (13S)-HODE ((13S)-hydroxy-(9Z,11E)-octadecadienoate) its major products (By similarity). During neuroinflammation, plays a role in neuronal secretion of specialized preresolving mediators (SPMs) 15R-lipoxin A4 that regulates phagocytic microglia (By similarity)","subcellular_location":"Microsome membrane; Endoplasmic reticulum membrane; Nucleus inner membrane; Nucleus outer membrane","url":"https://www.uniprot.org/uniprotkb/P35354/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PTGS2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PTGS2","total_profiled":1310},"omim":[{"mim_id":"621349","title":"PEROXIREDOXIN-LIKE 2B; PRXL2B","url":"https://www.omim.org/entry/621349"},{"mim_id":"618320","title":"SECRETORY PHOSPHOLIPASE A2, GROUP IIE; PLA2G2E","url":"https://www.omim.org/entry/618320"},{"mim_id":"617650","title":"PTGS2 ANTISENSE NFKB1 COMPLEX-MEDIATED EXPRESSION REGULATOR RNA, NONCODING; PACERR","url":"https://www.omim.org/entry/617650"},{"mim_id":"616793","title":"PHOSPHOLIPASE A2, GROUP IIF; PLA2G2F","url":"https://www.omim.org/entry/616793"},{"mim_id":"616473","title":"MICRO RNA 558; MIR558","url":"https://www.omim.org/entry/616473"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Vesicles","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":110.4},{"tissue":"seminal vesicle","ntpm":120.2},{"tissue":"urinary bladder","ntpm":151.3}],"url":"https://www.proteinatlas.org/search/PTGS2"},"hgnc":{"alias_symbol":["COX2"],"prev_symbol":[]},"alphafold":{"accession":"P35354","domains":[{"cath_id":"2.10.25.10","chopping":"28-69","consensus_level":"medium","plddt":95.5243,"start":28,"end":69},{"cath_id":"1.10.640.10","chopping":"183-422_508-583","consensus_level":"medium","plddt":95.9911,"start":183,"end":583}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P35354","model_url":"https://alphafold.ebi.ac.uk/files/AF-P35354-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P35354-F1-predicted_aligned_error_v6.png","plddt_mean":93.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PTGS2","jax_strain_url":"https://www.jax.org/strain/search?query=PTGS2"},"sequence":{"accession":"P35354","fasta_url":"https://rest.uniprot.org/uniprotkb/P35354.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P35354/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P35354"}},"corpus_meta":[{"pmid":"9929039","id":"PMC_9929039","title":"COX-2 inhibitors.","date":"1999","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/9929039","citation_count":823,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8181472","id":"PMC_8181472","title":"Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2.","date":"1994","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8181472","citation_count":353,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12612644","id":"PMC_12612644","title":"The development of COX2 inhibitors.","date":"2003","source":"Nature reviews. Drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/12612644","citation_count":313,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11566042","id":"PMC_11566042","title":"COX-1 and COX-2 inhibitors.","date":"2001","source":"Best practice & research. Clinical gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/11566042","citation_count":170,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19578162","id":"PMC_19578162","title":"Carvacrol, a component of thyme oil, activates PPARalpha and gamma and suppresses COX-2 expression.","date":"2010","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/19578162","citation_count":163,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29666475","id":"PMC_29666475","title":"lincRNA-Cox2 regulates NLRP3 inflammasome and autophagy mediated neuroinflammation.","date":"2018","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/29666475","citation_count":159,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31533781","id":"PMC_31533781","title":"miR-212-5p attenuates ferroptotic neuronal death after traumatic brain injury by targeting Ptgs2.","date":"2019","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/31533781","citation_count":146,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12846993","id":"PMC_12846993","title":"COX-2 and neurodegeneration in Parkinson's disease.","date":"2003","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/12846993","citation_count":130,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31162144","id":"PMC_31162144","title":"Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2).","date":"2019","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/31162144","citation_count":129,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11850206","id":"PMC_11850206","title":"Aromatase and COX-2 expression in human breast cancers.","date":"2001","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11850206","citation_count":119,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14733733","id":"PMC_14733733","title":"The role and regulation of COX-2 during viral infection.","date":"2003","source":"Viral immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14733733","citation_count":111,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15179623","id":"PMC_15179623","title":"COX-2 inhibition and lung cancer.","date":"2004","source":"Seminars in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15179623","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37705740","id":"PMC_37705740","title":"The PTGS2/COX2-PGE2 signaling cascade in inflammation: Pro or anti? A case study with type 1 diabetes mellitus.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37705740","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20047157","id":"PMC_20047157","title":"COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence.","date":"2010","source":"Current opinion in investigational drugs (London, England : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/20047157","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17901552","id":"PMC_17901552","title":"Function of COX-2 and prostaglandins in neurological disease.","date":"2007","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/17901552","citation_count":99,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15850674","id":"PMC_15850674","title":"New insights into COX-2 biology and inhibition.","date":"2005","source":"Brain research. Brain research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/15850674","citation_count":96,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18537668","id":"PMC_18537668","title":"COX-2 inhibition in schizophrenia and major depression.","date":"2008","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/18537668","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18482003","id":"PMC_18482003","title":"Complexity of COX-2 gene regulation.","date":"2008","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/18482003","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17609663","id":"PMC_17609663","title":"COX2 genetic variation, NSAIDs, and advanced prostate cancer risk.","date":"2007","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17609663","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20042743","id":"PMC_20042743","title":"Alteration of PTGS2 promoter methylation in chronic periodontitis.","date":"2009","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/20042743","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30404006","id":"PMC_30404006","title":"Genetic Models Reveal cis and trans Immune-Regulatory Activities for lincRNA-Cox2.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30404006","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22893198","id":"PMC_22893198","title":"Mechanistic aspects of COX-2 expression in colorectal neoplasia.","date":"2013","source":"Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22893198","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20656057","id":"PMC_20656057","title":"Citral, a component of lemongrass oil, activates PPARα and γ and suppresses COX-2 expression.","date":"2010","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/20656057","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14687789","id":"PMC_14687789","title":"HER2 and COX2 expression in human prostate cancer.","date":"2004","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/14687789","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23810915","id":"PMC_23810915","title":"PTGS2 (Cyclooxygenase-2) expression and survival among colorectal cancer patients: a systematic review.","date":"2013","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23810915","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16712449","id":"PMC_16712449","title":"The potential and rationale for COX-2 inhibitors in lung cancer.","date":"2006","source":"Anti-cancer agents in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16712449","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30679074","id":"PMC_30679074","title":"MicroRNA-26b relieves inflammatory response and myocardial remodeling of mice with myocardial infarction by suppression of MAPK pathway through binding to PTGS2.","date":"2019","source":"International journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/30679074","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33730589","id":"PMC_33730589","title":"COX2 regulates senescence secretome composition and senescence surveillance through PGE2.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33730589","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16785826","id":"PMC_16785826","title":"COX-2 and atherosclerosis.","date":"2006","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16785826","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12447099","id":"PMC_12447099","title":"COX-2 inhibitors and their role in gynecology.","date":"2002","source":"Obstetrical & gynecological survey","url":"https://pubmed.ncbi.nlm.nih.gov/12447099","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25619459","id":"PMC_25619459","title":"Atf3 negatively regulates Ptgs2/Cox2 expression during acute inflammation.","date":"2015","source":"Prostaglandins & other lipid mediators","url":"https://pubmed.ncbi.nlm.nih.gov/25619459","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29321644","id":"PMC_29321644","title":"COX-2 induces oncogenic micro RNA miR655 in human breast cancer.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29321644","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24447957","id":"PMC_24447957","title":"Role of PTGS2-generated PGE2 during gonadotrophin-induced bovine oocyte maturation and cumulus cell expansion.","date":"2013","source":"Reproductive biomedicine online","url":"https://pubmed.ncbi.nlm.nih.gov/24447957","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11102561","id":"PMC_11102561","title":"COX-2 and the kidneys.","date":"2000","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/11102561","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15979837","id":"PMC_15979837","title":"COX2 expression, angiogenesis, proliferation and survival in Barrett's cancer.","date":"2005","source":"European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15979837","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30119635","id":"PMC_30119635","title":"IL-33 facilitates proliferation of colorectal cancer dependent on COX2/PGE2.","date":"2018","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/30119635","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22425675","id":"PMC_22425675","title":"Prostanoids in tumor angiogenesis: therapeutic intervention beyond COX-2.","date":"2012","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22425675","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14529404","id":"PMC_14529404","title":"COX-2 and colorectal cancer.","date":"2003","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/14529404","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29381136","id":"PMC_29381136","title":"COX16 promotes COX2 metallation and assembly during respiratory complex IV biogenesis.","date":"2018","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/29381136","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14580367","id":"PMC_14580367","title":"Cyclooxygenase 2 (COX2)-prostanoid pathway and liver diseases.","date":"2003","source":"Prostaglandins, leukotrienes, and essential fatty acids","url":"https://pubmed.ncbi.nlm.nih.gov/14580367","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25797267","id":"PMC_25797267","title":"Ku80 cooperates with CBP to promote COX-2 expression and tumor growth.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25797267","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15883739","id":"PMC_15883739","title":"Positive feedback regulation of COX-2 expression by prostaglandin metabolites.","date":"2005","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/15883739","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33539521","id":"PMC_33539521","title":"Prostaglandin-Endoperoxide Synthase 2 (PTGS2) in the Oviduct: Roles in Fertilization and Early Embryo Development.","date":"2021","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33539521","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24423291","id":"PMC_24423291","title":"Hormonal therapy deregulates prostaglandin-endoperoxidase synthase 2 (PTGS2) expression in endometriotic tissues.","date":"2013","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24423291","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19643929","id":"PMC_19643929","title":"Distinct roles for basal and induced COX-2 in podocyte injury.","date":"2009","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19643929","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35485136","id":"PMC_35485136","title":"Suppression of lncRNA Gm47283 attenuates myocardial infarction via miR-706/ Ptgs2/ferroptosis axis.","date":"2022","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/35485136","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11967089","id":"PMC_11967089","title":"Gene transfer from mitochondrion to nucleus: novel mechanisms for gene activation from Cox2.","date":"2002","source":"The Plant journal : for cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11967089","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35017061","id":"PMC_35017061","title":"Macrophage COX2 Mediates Efferocytosis, Resolution Reprogramming, and Intestinal Epithelial Repair.","date":"2022","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/35017061","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28192229","id":"PMC_28192229","title":"HNE as an inducer of COX-2.","date":"2017","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28192229","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17097611","id":"PMC_17097611","title":"Ca2+ stimulates COX-2 expression through calcium-sensing receptor in fibroblasts.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17097611","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35184402","id":"PMC_35184402","title":"The CTCF/LncRNA-PACERR complex recruits E1A binding protein p300 to induce pro-tumour macrophages in pancreatic ductal adenocarcinoma via directly regulating PTGS2 expression.","date":"2022","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35184402","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15990700","id":"PMC_15990700","title":"COX-2 inhibitors and metabolism of essential fatty acids.","date":"2005","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/15990700","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17584101","id":"PMC_17584101","title":"COX-2: friend or foe?","date":"2007","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/17584101","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27750221","id":"PMC_27750221","title":"Transgenic expression of cyclooxygenase-2 (COX2) causes premature aging phenotypes in mice.","date":"2016","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/27750221","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23629521","id":"PMC_23629521","title":"Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer.","date":"2013","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23629521","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25371669","id":"PMC_25371669","title":"COX-2 Inhibitors and Gastric Cancer.","date":"2014","source":"Gastroenterology research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/25371669","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31518663","id":"PMC_31518663","title":"Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer.","date":"2019","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/31518663","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35910805","id":"PMC_35910805","title":"DCLK1 promotes colorectal cancer stemness and aggressiveness via the XRCC5/COX2 axis.","date":"2022","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/35910805","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30740906","id":"PMC_30740906","title":"Activation of PTGS2/NF-κB signaling pathway enhances radiation resistance of glioma.","date":"2019","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30740906","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36569299","id":"PMC_36569299","title":"Atorvastatin attenuates ferroptosis-dependent myocardial injury and inflammation following coronary microembolization via the Hif1a/Ptgs2 pathway.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36569299","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11566043","id":"PMC_11566043","title":"COX-2 inhibition and prevention of cancer.","date":"2001","source":"Best practice & research. Clinical gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/11566043","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19327107","id":"PMC_19327107","title":"Association of polymorphisms of PTGS2 and CYP8A1 with myocardial infarction.","date":"2009","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19327107","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32054883","id":"PMC_32054883","title":"Downregulation of peripheral PTGS2/COX-2 in response to valproate treatment in patients with epilepsy.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32054883","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23392729","id":"PMC_23392729","title":"Endotoxins potentiate COX-2 and RANKL expression in compressed PDL cells.","date":"2013","source":"Clinical oral investigations","url":"https://pubmed.ncbi.nlm.nih.gov/23392729","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25703332","id":"PMC_25703332","title":"Disruption of CTCF/cohesin-mediated high-order chromatin structures by DNA methylation downregulates PTGS2 expression.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25703332","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16226033","id":"PMC_16226033","title":"Roles of LPA3 and COX-2 in implantation.","date":"2005","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/16226033","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29154948","id":"PMC_29154948","title":"The mitochondrial TMEM177 associates with COX20 during COX2 biogenesis.","date":"2017","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/29154948","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21437756","id":"PMC_21437756","title":"COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma.","date":"2011","source":"Annals of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21437756","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33444716","id":"PMC_33444716","title":"Naoxintong restores ischemia injury and inhibits thrombosis via COX2-VEGF/ NFκB signaling.","date":"2021","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33444716","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24051096","id":"PMC_24051096","title":"Elevated COX2 expression and PGE2 production by downregulation of RXRα in senescent macrophages.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24051096","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31581537","id":"PMC_31581537","title":"Inhibitors of Oxidative Phosphorylation Modulate Astrocyte Inflammatory Responses through AMPK-Dependent Ptgs2 mRNA Stabilization.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31581537","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14529401","id":"PMC_14529401","title":"Mucosal repair and COX-2 inhibition.","date":"2003","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/14529401","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19455278","id":"PMC_19455278","title":"Functional polymorphisms of the cyclooxygenase (PTGS2) gene and risk for gallbladder cancer in a North Indian population.","date":"2009","source":"Journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/19455278","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39292340","id":"PMC_39292340","title":"Resveratrol Protects Müller Cells Against Ferroptosis in the Early Stage of Diabetic Retinopathy by Regulating the Nrf2/GPx4/PTGS2 Pathway.","date":"2024","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/39292340","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10704568","id":"PMC_10704568","title":"Cox-2 expression in retinoblastoma.","date":"2000","source":"American journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/10704568","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18667730","id":"PMC_18667730","title":"Gq-dependent signaling upregulates COX2 in glomerular podocytes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/18667730","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34786060","id":"PMC_34786060","title":"LncRNA PTGS2 regulates islet β-cell function through the miR-146a-5p/RBP4 axis and its diagnostic value in type 2 diabetes mellitus.","date":"2021","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/34786060","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24970799","id":"PMC_24970799","title":"Post-translational regulation of COX2 activity by FYN in prostate cancer cells.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24970799","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11336566","id":"PMC_11336566","title":"COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention.","date":"2001","source":"Expert opinion on pharmacotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/11336566","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37204627","id":"PMC_37204627","title":"Tetrandrine Represses Inflammation and Attenuates Osteoarthritis by Selective Inhibition of COX-2.","date":"2023","source":"Current medical science","url":"https://pubmed.ncbi.nlm.nih.gov/37204627","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36327673","id":"PMC_36327673","title":"LPS-induced PTGS2 manipulates the inflammatory response through trophoblast invasion in preeclampsia via NF-κB pathway.","date":"2022","source":"Reproductive biology","url":"https://pubmed.ncbi.nlm.nih.gov/36327673","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34115526","id":"PMC_34115526","title":"FCER1G and PTGS2 Serve as Potential Diagnostic Biomarkers of Acute Myocardial Infarction Based on Integrated Bioinformatics Analyses.","date":"2021","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/34115526","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35073820","id":"PMC_35073820","title":"miR-26a-5p suppresses nasopharyngeal carcinoma progression by inhibiting PTGS2 expression.","date":"2022","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/35073820","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35602948","id":"PMC_35602948","title":"NR5A2/LRH-1 regulates the PTGS2-PGE2-PTGER1 pathway contributing to pancreatic islet survival and function.","date":"2022","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/35602948","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35280679","id":"PMC_35280679","title":"LncRNA-COX2 inhibits Fibroblast Activation and Epidural Fibrosis by Targeting EGR1.","date":"2022","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35280679","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23967159","id":"PMC_23967159","title":"A meta-analysis of PTGS1 and PTGS2 polymorphisms and NSAID intake on the risk of developing cancer.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23967159","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38514006","id":"PMC_38514006","title":"PTGS2: A potential immune regulator and therapeutic target for chronic spontaneous urticaria.","date":"2024","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38514006","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31616930","id":"PMC_31616930","title":"Ablation of conceptus PTGS2 expression does not alter early conceptus development and establishment of pregnancy in the pig†.","date":"2020","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/31616930","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27534811","id":"PMC_27534811","title":"A small amount of cyclooxygenase 2 (COX2) is constitutively expressed in platelets.","date":"2016","source":"Platelets","url":"https://pubmed.ncbi.nlm.nih.gov/27534811","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34067294","id":"PMC_34067294","title":"Circulating PTGS2, JAG1, GUCY2C and PGF mRNA in Peripheral Blood and Serum as Potential Biomarkers for Patients with Metastatic Colon Cancer.","date":"2021","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34067294","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36875123","id":"PMC_36875123","title":"The roles of COX-2 in protozoan infection.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36875123","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25467164","id":"PMC_25467164","title":"Inhibition of FAAH, TRPV1, and COX2 by NSAID-serotonin conjugates.","date":"2014","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/25467164","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25624863","id":"PMC_25624863","title":"Association study of COX-2 (PTGS2) -765 G/C promoter polymorphism by pyrosequencing in Sicilian patients with Alzheimer's disease.","date":"2014","source":"Archives of medical science : AMS","url":"https://pubmed.ncbi.nlm.nih.gov/25624863","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32168749","id":"PMC_32168749","title":"Evaluation of Glycosylated PTGS2 in Colorectal Cancer for NSAIDS-Based Adjuvant Therapy.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32168749","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38762541","id":"PMC_38762541","title":"Endothelial ROBO4 suppresses PTGS2/COX-2 expression and inflammatory diseases.","date":"2024","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/38762541","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25795373","id":"PMC_25795373","title":"Growth Factors and COX2 Expression in Canine Perivascular Wall Tumors.","date":"2015","source":"Veterinary pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25795373","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32100450","id":"PMC_32100450","title":"Association between COX-2 and 15-PGDH polymorphisms and SLE susceptibility.","date":"2020","source":"International journal of rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32100450","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30051683","id":"PMC_30051683","title":"COX-2 Expression in Breast Carcinoma with Correlation to Clinicopathological Parameters.","date":"2018","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/30051683","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27624482","id":"PMC_27624482","title":"Activin A upregulates PTGS2 expression and increases PGE2 production in human granulosa-lutein cells.","date":"2016","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/27624482","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21248286","id":"PMC_21248286","title":"Resveratrol modulates the expression of PTGS2 and cellular proliferation in the normal rat endometrium in an AKT-dependent manner.","date":"2011","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/21248286","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9630216","id":"PMC_9630216","title":"Cyclooxygenase regulates angiogenesis induced by colon cancer cells.","date":"1998","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9630216","citation_count":2060,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1380156","id":"PMC_1380156","title":"Human cyclooxygenase-2 cDNA.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1380156","citation_count":1379,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12391014","id":"PMC_12391014","title":"Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals.","date":"2002","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12391014","citation_count":1306,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7510883","id":"PMC_7510883","title":"Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7510883","citation_count":917,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15766526","id":"PMC_15766526","title":"Involvement of microRNA in AU-rich element-mediated mRNA instability.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/15766526","citation_count":690,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8473346","id":"PMC_8473346","title":"Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8473346","citation_count":663,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20733059","id":"PMC_20733059","title":"Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression.","date":"2010","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/20733059","citation_count":654,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"4514999","id":"PMC_4514999","title":"Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis.","date":"1973","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/4514999","citation_count":644,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17429393","id":"PMC_17429393","title":"Mediators of vascular remodelling co-opted for sequential steps in lung metastasis.","date":"2007","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/17429393","citation_count":554,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16373578","id":"PMC_16373578","title":"Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2.","date":"2005","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/16373578","citation_count":429,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7945196","id":"PMC_7945196","title":"Structure of the human cyclo-oxygenase-2 gene.","date":"1994","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/7945196","citation_count":426,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21972293","id":"PMC_21972293","title":"Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21972293","citation_count":425,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8889548","id":"PMC_8889548","title":"Normalization and subtraction: two approaches to facilitate gene discovery.","date":"1996","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/8889548","citation_count":401,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29656893","id":"PMC_29656893","title":"DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity.","date":"2018","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/29656893","citation_count":379,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20448152","id":"PMC_20448152","title":"Cyclooxygenase-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes.","date":"2010","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20448152","citation_count":373,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16952555","id":"PMC_16952555","title":"Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine.","date":"2006","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/16952555","citation_count":367,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18550243","id":"PMC_18550243","title":"Air pollution, cognitive deficits and brain abnormalities: a pilot study with children and dogs.","date":"2008","source":"Brain and cognition","url":"https://pubmed.ncbi.nlm.nih.gov/18550243","citation_count":366,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12377741","id":"PMC_12377741","title":"Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response.","date":"2002","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12377741","citation_count":310,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9140046","id":"PMC_9140046","title":"Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function.","date":"1997","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9140046","citation_count":304,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7947975","id":"PMC_7947975","title":"Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system.","date":"1994","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/7947975","citation_count":295,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18843292","id":"PMC_18843292","title":"Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction.","date":"2008","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/18843292","citation_count":293,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12835322","id":"PMC_12835322","title":"Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12835322","citation_count":290,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18347602","id":"PMC_18347602","title":"Genomewide association for schizophrenia in the CATIE study: results of stage 1.","date":"2008","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/18347602","citation_count":290,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9545330","id":"PMC_9545330","title":"Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9545330","citation_count":275,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49709,"output_tokens":5886,"usd":0.118708},"stage2":{"model":"claude-opus-4-6","input_tokens":9509,"output_tokens":3659,"usd":0.20853},"total_usd":0.750068,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":63471,"output_tokens":9126,"usd":0.163652},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":13197,"output_tokens":4272,"usd":0.259178}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"PTGS2 gene encodes an inducible isozyme of prostaglandin-endoperoxide synthase distinct from the constitutive PTGS1; the gene spans >8.3 kb, consists of 10 exons, and contains regulatory elements including NF-κB, CRE, AP-1, and TATA box in its 5'-flanking region; PTGS2 maps to chromosome 1q25.2-q25.3, distinct from PTGS1 on chromosome 9q32-q33.3\",\n      \"method\": \"PCR cloning, nucleotide sequence analysis, primer extension, fluorescence in situ hybridization\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original structural/genomic characterization with multiple orthogonal methods\",\n      \"pmids\": [\"8181472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FYN tyrosine kinase directly phosphorylates COX-2 at Tyr446; phospho-mimetic mutation at this site increases COX-2 enzymatic activity while phosphorylation-blocking mutation prevents FYN-mediated activation, establishing post-translational regulation of COX-2 activity independent of protein expression changes\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis, prostaglandin activity assay\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro assay with mutagenesis identifying specific phosphorylation site and functional consequence\",\n      \"pmids\": [\"24970799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ATF3 (activating transcription factor-3) is a transcriptional repressor that negatively regulates Ptgs2 expression; ATF3 accumulates in the nucleus of activated macrophages and is recruited to the Ptgs2 promoter via chromatin immunoprecipitation; Atf3-/- macrophages show significantly higher Ptgs2 expression and prostaglandin production upon stimulation\",\n      \"method\": \"Chromatin immunoprecipitation, Atf3 knockout mice, peritoneal macrophage isolation, RT-PCR, ELISA\",\n      \"journal\": \"Prostaglandins & other lipid mediators\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrating direct promoter binding, confirmed in knockout model in vitro and in vivo\",\n      \"pmids\": [\"25619459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DNA methylation of the PTGS2 CpG island disrupts CTCF/cohesin-mediated chromatin looping at the PTGS2 locus, abrogating enrichment of positive elongation factor b at the transcriptional start site and thereby downregulating PTGS2 expression\",\n      \"method\": \"ChIP, chromatin conformation analysis, DNA methylation assay, siRNA knockdown, reporter assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (ChIP, chromatin looping, methylation) establishing mechanistic link\",\n      \"pmids\": [\"25703332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Ku80 binds the COX-2 gene promoter and upregulates COX-2 promoter activity and expression in lung cancer cells; CBP (transcription co-activator) interacts with and acetylates Ku80 to co-regulate COX-2 promoter activation; Ku80 knockdown suppresses ERK phosphorylation and MAPK pathway inactivation\",\n      \"method\": \"Streptavidin-agarose pulldown, proteomics, siRNA knockdown, co-immunoprecipitation, reporter assay, xenograft mouse model\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, pulldown with proteomics, functional knockdown with in vivo validation\",\n      \"pmids\": [\"25797267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Prostaglandin metabolites (PGE2 and 15d-PGJ2) induce positive feedback upregulation of COX-2 protein and mRNA expression in mouse lung fibroblasts, without affecting COX-1 or cPLA2, indicating autocrine amplification of COX-2 expression by its own products\",\n      \"method\": \"Cell treatment with PG metabolites, Western blot, RT-PCR, prostaglandin ELISA\",\n      \"journal\": \"Inflammation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean cell-based assay with dose-response, single lab\",\n      \"pmids\": [\"15883739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Calcium-sensing receptor (CasR) activation by elevated extracellular Ca2+ stimulates COX-2 mRNA and protein expression in jaw cyst fibroblasts via PLC-dependent activation of ERK1/2, p38 MAPK, and JNK signaling pathways\",\n      \"method\": \"Pharmacological inhibitors, RT-PCR, Western blot, intracellular Ca2+ measurement (fluo-3), IP3 assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple signaling inhibitors with pathway dissection, single lab\",\n      \"pmids\": [\"17097611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Gq-alpha constitutively active signaling stimulates calcineurin/NFAT pathway to upregulate COX-2 mRNA and protein in glomerular podocytes, resulting in increased PGE2 production and podocyte death; selective COX-2 inhibition attenuates this injury\",\n      \"method\": \"TAT-protein transduction of constitutively active Gqα, reporter assay, RT-PCR, Western blot, transgenic mouse model, COX-2 inhibitor treatment\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — both in vitro transduction and in vivo transgenic model confirming pathway\",\n      \"pmids\": [\"18667730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"COX-2 overexpression in podocytes increases susceptibility to puromycin-induced injury through thromboxane receptor (TP) activation via elevated thromboxane B2; genetic deletion of TP prevents adriamycin-induced podocyte injury in COX-2-overexpressing mice, whereas basal COX-2 expression is required for podocyte survival\",\n      \"method\": \"Transgenic COX-2 overexpression, COX-2 knockout mice, conditional prostanoid receptor knockouts, pharmacological TP/EP4 antagonism, albuminuria measurement, foot process morphology\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic models with defined receptor-specific phenotypic readouts\",\n      \"pmids\": [\"19643929\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Transgenic post-natal overexpression of COX2 in mice causes premature aging phenotypes including increased p16, p53, and phospho-H2AX expression in tissues, and increased senescence-associated β-galactosidase in lung fibroblasts, establishing a causal role for COX2 in aging\",\n      \"method\": \"Inducible COX2 transgenic mouse model, Western blot for aging markers, SA-β-gal staining\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo transgenic model with defined phenotype, single lab\",\n      \"pmids\": [\"27750221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"4-Hydroxy-2-nonenal (HNE) induces COX-2 expression through stabilization of COX-2 mRNA via p38 MAPK signaling; this induction requires a serum component identified as modified/oxidized LDL; HNE-induced COX-2 overexpression is linked to p53 accumulation and downregulation of a proteasome subunit\",\n      \"method\": \"mRNA stability assays, p38 MAPK inhibition, immunoblotting, cell-based mechanistic studies\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple mechanistic steps established in cell-based assays, single lab\",\n      \"pmids\": [\"28192229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"EPHA2 signaling through TGFβ drives PTGS2 expression in tumor cells to suppress T-cell infiltration and promote immune exclusion in pancreatic adenocarcinoma; Ptgs2 deletion reverses T-cell exclusion and sensitizes tumors to immunotherapy similarly to Epha2 deletion\",\n      \"method\": \"Genetic deletion (Epha2 and Ptgs2 knockout), pharmacological inhibition, tumor immune phenotyping, in vivo mouse models\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis established by double genetic deletion with defined immunological phenotype, replicated pharmacologically\",\n      \"pmids\": [\"31162144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"COX2 (PTGS2) is a critical regulator of SASP composition in RAS-induced senescent cells through an autocrine feedback loop: COX2-derived PGE2 binds EP4 receptor to regulate multiple inflammatory SASP components; in vivo, Cox2 is required for Cxcl1 expression, immune-mediated senescence surveillance, and tumor suppression during hepatocyte senescence\",\n      \"method\": \"RAS-induced senescence model, Cox2 knockout, in vivo hepatic senescence surveillance assay, immune cell phenotyping, pharmacological COX2 inhibition\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with in vivo functional readout, autocrine mechanism defined pharmacologically\",\n      \"pmids\": [\"33730589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Macrophage COX2 potentiates efferocytosis by affecting apoptotic cell binding capacity; COX2 modulates efferocytosis-dependent eicosanoid production (PGI2, PGE2, lipoxin A4, 15d-PGJ2); macrophage COX2 mediates efferocytosis-induced intestinal epithelial repair in organoid co-culture model\",\n      \"method\": \"Macrophage-specific Cox2 knockout, pharmacological COX2 inhibition, eicosanoid lipidomics by LC-MS/MS, small intestinal epithelial organoids, efferocytosis assay\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific KO with multiple orthogonal functional assays and lipidomics\",\n      \"pmids\": [\"35017061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"DCLK1 kinase binds and phosphorylates XRCC5, which in turn transcriptionally activates COX-2 (PTGS2) expression and enhances PGE2 production in colorectal cancer cells, generating an inflammatory tumor microenvironment\",\n      \"method\": \"Co-immunoprecipitation, proteomics, kinase assay, luciferase reporter, DCLK1 inhibition in CRC mouse models\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus kinase assay plus in vivo model, single lab\",\n      \"pmids\": [\"35910805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ROBO4 suppresses PTGS2/COX-2 expression in endothelial cells by interacting with IQGAP1 and the ubiquitin E3 ligase TRAF7; ROBO4 enhances IQGAP1 ubiquitination through TRAF7, inhibiting prolonged RAC1 activation and thereby decreasing PTGS2 expression; Robo4-deficient mice show exacerbated PTGS2-associated inflammatory diseases\",\n      \"method\": \"RNA-seq, Co-IP, ubiquitination assay, RAC1 activity assay, Robo4 knockout mice, arthritis/edema models\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic complex identified by Co-IP with functional in vivo validation in knockout mice\",\n      \"pmids\": [\"38762541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The CTCF/lncRNA-PACERR complex recruits histone acetyltransferase p300 to the PTGS2 promoter, enhancing histone acetylation and transcription of PTGS2 in tumor-associated macrophages to promote M2 polarization in pancreatic adenocarcinoma\",\n      \"method\": \"ChIP-seq, ATAC-seq, RNA-ChIP (CHIRP-seq), RNA immunoprecipitation, RNA pulldown, lentiviral knockdown, in vitro and in vivo invasion assays\",\n      \"journal\": \"Clinical and translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal genomic and biochemical methods establishing complex and functional consequence\",\n      \"pmids\": [\"35184402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PTGS2-derived PGE2 signals via the EP4 receptor to activate ERK1/2 and P38 MAPK pathways, which upregulate BCL2 expression and mediate resistance to cisplatin-induced apoptosis in gastric cancer; cisplatin induces PTGS2 expression through ROS/NF-κB pathway\",\n      \"method\": \"siRNA knockdown, pharmacological inhibition (celecoxib), Western blot, xenograft mouse model, clinical specimen correlation\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway dissection with genetic and pharmacological tools, in vivo validation, single lab\",\n      \"pmids\": [\"31518663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PTGS2 activates NF-κB signaling pathway and prevents DNA damage response after radiotherapy, leading to radioresistance in glioma cells; PTGS2 overexpression decreases G2/M arrest post-radiation while knockdown increases it\",\n      \"method\": \"siRNA/overexpression constructs, clonogenic survival assay, flow cytometry (cell cycle), Western blot for NF-κB pathway components, immunofluorescence for γH2AX\",\n      \"journal\": \"Cancer medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional genetic manipulation with mechanistic readouts, single lab\",\n      \"pmids\": [\"30740906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PTGS2 (COX-2) expression in bovine cumulus-oocyte complexes is upregulated during gonadotrophin-stimulated maturation; PTGS2-derived PGE2 acting via the PTGER2 receptor plays a role in the timing of nuclear maturation (predominantly the MI-to-MII transition) but not cumulus expansion in bovine oocytes\",\n      \"method\": \"PTGS2-specific siRNA, selective COX-2 inhibitor (NS398), PTGER2 antagonist (AH6809), nuclear maturation assessment, embryo development follow-up\",\n      \"journal\": \"Reproductive biomedicine online\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA plus pharmacological inhibition with receptor-specific antagonist, single lab\",\n      \"pmids\": [\"24447957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Activin A upregulates PTGS2 expression and PGE2 production in human granulosa-lutein cells via ACVR1B-mediated SMAD2/3-SMAD4 signaling pathway\",\n      \"method\": \"TGF-β/activin receptor inhibitor (SB431542), siRNA knockdown of pathway components, RT-PCR, Western blot, ELISA\",\n      \"journal\": \"Reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor and downstream signaling dissection with siRNA and inhibitors, single lab\",\n      \"pmids\": [\"27624482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NR5A2/LRH-1 regulates PTGS2 expression in pancreatic islet beta cells; LRH-1 agonist BL001 protection against apoptosis requires LRH-1, PTGS2-derived PGE2, and PTGER1 signaling, defining the LRH-1/PTGS2/PGE2/PTGER1 axis in beta cell survival\",\n      \"method\": \"Beta-cell-specific LRH-1 knockout mice, PTGS2 inactivation, PTGER1 antagonist (ONO-8130), cytokine challenge, cytochrome c release assay, cleaved-PARP measurement\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO models combined with pharmacological pathway dissection in vivo and in vitro\",\n      \"pmids\": [\"35602948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Hif1a (hypoxia-inducible factor 1α) transcription factor binds to the Ptgs2 promoter and upregulates its expression; the Hif1a/Ptgs2 axis drives ferroptosis and inflammation following coronary microembolization, which is inhibited by atorvastatin\",\n      \"method\": \"Chromatin immunoprecipitation, Ptgs2 siRNA silencing, rat CME model, ferroptosis markers (MDA, Fe2+, GSH, GPx4)\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP establishing direct promoter binding, confirmed with gene silencing in vivo, single lab\",\n      \"pmids\": [\"36569299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"AMPK activation following mitochondrial oxidative phosphorylation inhibition stabilizes Ptgs2 mRNA in astrocytes, increasing COX-2 protein and eicosanoid secretion; AMPK silencing prevents this Ptgs2 mRNA stabilization\",\n      \"method\": \"Mitochondrial complex inhibitors, AMPK siRNA knockdown, AMPK activators, mRNA stability assays, LC/MS for eicosanoid measurement\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA plus pharmacological tools establishing AMPK-Ptgs2 mRNA stability axis, single lab\",\n      \"pmids\": [\"31581537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PTGS2 promoter methylation is inversely associated with PTGS2 mRNA transcription in periodontally inflamed gingival tissue; specific methylation at -458 bp inversely correlates with PTGS2 expression, indicating epigenetic regulation of PTGS2 expression in chronic inflammation\",\n      \"method\": \"Bisulfite pyrosequencing, RT-PCR, gingival biopsy analysis\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — correlative methylation-expression analysis in clinical tissue, single study\",\n      \"pmids\": [\"20042743\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PTGS2/COX-2 is an inducible enzyme that catalyzes the rate-limiting conversion of arachidonic acid to prostaglandin H2 (PGH2), which is subsequently converted to downstream prostanoids (PGE2, PGI2, TXA2, etc.); its expression is tightly regulated at transcriptional level by NF-κB, CTCF/cohesin-mediated chromatin looping, DNA methylation, and transcriptional repressors such as ATF3, and at post-transcriptional level by mRNA stabilization via p38 MAPK and AMPK; post-translationally, FYN phosphorylates COX-2 at Tyr446 to increase its enzymatic activity; upstream signaling through EPHA2-TGFβ, Gq-calcineurin, LRH-1, activin A-SMAD2/3, and Hif1a drives PTGS2 transcription, while ROBO4 suppresses it via TRAF7-mediated IQGAP1 ubiquitination and RAC1 inhibition; COX-2-derived PGE2 engages EP2/EP4 receptors in autocrine feedback to further amplify COX-2 expression and mediates diverse downstream effects including senescence surveillance, efferocytosis, immune suppression in tumors, podocyte injury via thromboxane receptor, and beta cell survival.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"Human COX-2 (PTGS2) was cloned from umbilical vein endothelial cells; its cDNA encodes a 604-amino-acid polypeptide 61% identical to COX-1, and expression of the open reading frame in COS-7 cells confers cyclooxygenase activity, demonstrating it is a functional prostaglandin H synthase. COX-2 mRNA was preferentially induced by PMA and LPS in endothelial cells and monocytes.\",\n      \"method\": \"Molecular cloning, in vitro translation, heterologous expression in COS-7 cells with enzymatic activity assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution of enzymatic activity in heterologous cells; foundational cloning paper\",\n      \"pmids\": [\"1380156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Human PHS II (PTGS2) was independently cloned from an endothelial cell cDNA library; the protein shares 61% identity with PHS I, maps to chromosome 1 (distinct from PHS I on chromosome 9), and its mRNA is induced by TNF, PMA, LPS, and IL-1 in endothelial cells, with induction correlating with increased prostacyclin biosynthesis. Cycloheximide induced mRNA without activity increase, confirming translation is required for functional enzyme.\",\n      \"method\": \"Molecular cloning, chromosomal mapping (Southern analysis), mRNA induction assays, prostacyclin biosynthesis measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — independent cloning with functional correlation; replicated foundational result\",\n      \"pmids\": [\"8473346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Structure of the human COX-2 gene (PTGS2) was determined: 10 exons spanning ~8.3 kb, mapped to chromosome 1q25.2-q25.3 (distinct from PTGS1 at 9q32-q33.3). The 5'-flanking region contains a TATA box and regulatory elements including NF-κB, CRE, AP-2, SP1, and Ets-1 sites. The large 3'-UTR exon contains 22 copies of the AUUUA mRNA instability element, indicating post-transcriptional regulation.\",\n      \"method\": \"Genomic library screening, DNA sequencing, primer extension, fluorescence in situ hybridization (FISH)\",\n      \"journal\": \"European journal of biochemistry / The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — complete gene structure determination with functional regulatory element identification; two independent reports\",\n      \"pmids\": [\"8181472\", \"7945196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Recombinant human PTGS2 (PGHS-2) expressed in a baculovirus system possesses both cyclooxygenase and peroxidase activities, has high affinity for arachidonate as substrate, and undergoes self-inactivation during catalysis. The enzyme is glycosylated with heterogeneous glycosylation, and certain NSAIDs selectively inhibit PGHS-2 over PGHS-1.\",\n      \"method\": \"Baculovirus expression, enzyme purification, kinetic assays (cyclooxygenase and peroxidase activities), SDS-PAGE, N-terminal sequencing\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purified recombinant enzyme with in vitro activity characterization and kinetics\",\n      \"pmids\": [\"7947975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"COX-2 protein is constitutively expressed at a basal level in granulomatous tissue during the chronic phase of murine inflammation, and COX-2 protein rises progressively during inflammation peaking at day 14, while COX-1 protein remains unaltered throughout—establishing distinct regulatory behavior for the two isoforms in vivo.\",\n      \"method\": \"Western blot, enzymatic activity assay in murine air-pouch granuloma model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct protein quantification with functional readout in defined in vivo inflammatory model\",\n      \"pmids\": [\"7510883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PTGS2 (COX-2) subcellular localization was determined by immunoelectron microscopy: both PGHS-1 and PGHS-2 reside on the lumenal surfaces of the endoplasmic reticulum and nuclear envelope (inner and outer nuclear membranes) in human monocytes, NIH 3T3 cells, and HUVECs. Subcellular fractionation and isozyme-specific inhibitor studies confirm similar distribution and product profiles, indicating independent functioning is not attributable to different subcellular compartments.\",\n      \"method\": \"Immunoelectron microscopy, subcellular fractionation, Western blotting, isozyme-selective inhibitor product analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — high-resolution localization with orthogonal biochemical validation across multiple cell types\",\n      \"pmids\": [\"9545330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"COX-2-overexpressing colon carcinoma cells stimulate endothelial cell migration and tube formation (angiogenesis) through production of prostaglandins and proangiogenic factors; selective COX-2 inhibitor NS-398 blocks this effect. COX-1 in endothelial cells also regulates angiogenesis independently, as shown by COX-1 antisense inhibition of tube formation, establishing a dual-mechanism model for cyclooxygenase regulation of tumor angiogenesis.\",\n      \"method\": \"In vitro coculture angiogenesis assay, COX-2 overexpression, NS-398 inhibition, neutralizing antibodies to angiogenic factors, COX-1 antisense oligonucleotides\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic cell-based assays with genetic and pharmacological perturbation; highly cited foundational paper\",\n      \"pmids\": [\"9630216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"In adult human kidney, COX-2 immunoreactivity localizes to endothelial and smooth muscle cells of arteries and veins and to intraglomerular podocytes (not macula densa, unlike rat), suggesting a primary role in regulation of renal perfusion and glomerular hemodynamics. In fetal kidney, COX-2 appears in podocytes only at the end-stage of renal development.\",\n      \"method\": \"Immunohistology, in situ mRNA hybridization with digoxigenin-labeled riboprobes\",\n      \"journal\": \"The American journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization by two independent methods with species-specific and developmental resolution\",\n      \"pmids\": [\"9140046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Aspirin acetylates COX-2, switching its oxygenation of DHA from 13-HDHA to 17R-HDHA; human COX-2 converts DHA to 13-hydroxy-DHA which is redirected by aspirin-acetylation to 17R-HDHA, the precursor of anti-inflammatory resolvins. This demonstrates that aspirin-acetylated COX-2 retains oxygenase activity but with altered stereospecificity, enabling biosynthesis of pro-resolution lipid mediators.\",\n      \"method\": \"Lipidomic analysis (LC-MS), in vitro enzyme assays with aspirin-treated human COX-2, isotope labeling, cell-based experiments with human microglial and endothelial cells\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mechanistic in vitro enzyme assay with product characterization and functional validation; seminal resolvin discovery paper\",\n      \"pmids\": [\"12391014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"A common COX-2 promoter variant (-765G>C) significantly reduces promoter activity (~28-31% lower) in human lung fibroblasts basally and in serum-stimulated conditions. Carriers of the -765C allele show lower post-operative CRP elevation after coronary bypass surgery, linking reduced PTGS2 promoter activity to attenuated acute-phase inflammatory response in vivo.\",\n      \"method\": \"Reporter gene assay, PCR-based variant screening, clinical association study with plasma CRP measurement\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional promoter assay replicated by clinical phenotype correlation\",\n      \"pmids\": [\"12377741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Membrane-bound prostaglandin E synthase-2 (mPGES-2), while constitutively expressed, promotes PGE2 production via both COX-1 and COX-2 with modest COX-2 preference, in contrast to mPGES-1 which preferentially couples to COX-2. This establishes that PTGS2 (COX-2) can functionally couple with multiple downstream prostaglandin synthases.\",\n      \"method\": \"Cell-based overexpression, isozyme-selective inhibitor studies, PGE2 measurement by immunoassay, subcellular fractionation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional coupling demonstrated in multiple cell lines with orthogonal methods\",\n      \"pmids\": [\"12835322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Inducible nitric oxide synthase (iNOS) physically binds to COX-2 (PTGS2) and S-nitrosylates it, enhancing COX-2 catalytic activity. Selectively disrupting the iNOS–COX-2 binding interaction prevents NO-mediated activation of COX-2, establishing a direct protein–protein interaction that amplifies inflammatory signaling.\",\n      \"method\": \"Co-immunoprecipitation, S-nitrosylation assay, selective disruption of protein-protein interaction, in vitro activity assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct binding demonstrated by Co-IP with functional consequence via activity assay and disruption experiment\",\n      \"pmids\": [\"16373578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"miR-16, containing a sequence complementary to the AU-rich element (ARE) in the COX-2 3'-UTR, is required for ARE-mediated mRNA turnover of COX-2 mRNA. miR-16 works in concert with the ARE-binding protein tristetraprolin (TTP) through association with Ago/eiF2C family members to target ARE-containing mRNAs for degradation, establishing a microRNA-dependent mechanism for post-transcriptional regulation of PTGS2.\",\n      \"method\": \"RNAi screen in Drosophila S2 cells, siRNA knockdown in HeLa cells, mRNA stability assays, sequence-specificity controls\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic finding replicated across species with sequence-specific controls and protein interaction evidence\",\n      \"pmids\": [\"15766526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TLR4 signaling via MyD88 is required for optimal Cox-2 expression in intestinal epithelial cells; LPS-mediated PGE2 production is blocked by Cox-2 inhibition or siRNA against MyD88. TLR4-deficient mice show reduced proliferation and increased apoptosis after DSS injury, which is rescued by exogenous PGE2, establishing that PTGS2-derived PGE2 downstream of TLR4 is essential for intestinal epithelial repair, potentially through transactivation of the EGF receptor.\",\n      \"method\": \"Reporter luciferase assay, siRNA knockdown, immunohistochemistry, Western blotting, BrdU/TUNEL assays in TLR4-/- mice, PGE2 rescue experiments\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo combined with pharmacological and siRNA evidence; multiple orthogonal readouts\",\n      \"pmids\": [\"16952555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"COX-2 (PTGS2), together with epiregulin and matrix metalloproteinases 1 and 2, facilitates assembly of new tumor blood vessels, release of tumor cells into circulation, and breaching of lung capillaries to seed pulmonary metastasis from breast cancer cells. Genetic and pharmacological approaches in human breast cancer cells and xenograft models established COX2 as a mediator of vascular remodeling co-opted for lung metastasis.\",\n      \"method\": \"Genetic perturbation (shRNA knockdown), pharmacological inhibition, xenograft mouse models, in vitro vascular permeability and angiogenesis assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — combined genetic and pharmacological epistasis with defined in vivo metastatic phenotype readout\",\n      \"pmids\": [\"17429393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"COX-2 is a downstream effector of β-adrenergic signaling in white adipose tissue (WAT) and is required for induction of brown adipose tissue (BAT) in WAT depots. Prostaglandins produced by COX-2 shift differentiation of mesenchymal progenitors toward a brown adipocyte phenotype. COX-2 overexpression in WAT induced de novo BAT recruitment, increased systemic energy expenditure, and protected mice against diet-induced obesity.\",\n      \"method\": \"Cox-2 transgenic mouse model (WAT-specific overexpression), Cox-2 genetic deletion, mesenchymal progenitor differentiation assays, metabolic phenotyping\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function genetic mouse models with mechanistic cell differentiation assay\",\n      \"pmids\": [\"20448152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Increasing matrix stiffness across the pathophysiological range strongly suppresses fibroblast COX-2 expression and PGE2 synthesis. Exogenous PGE2 or EP2 receptor agonist completely counteracts the proliferative and matrix-synthetic effects of increased stiffness, establishing an autocrine feedback loop in which COX-2-derived PGE2 maintains fibroblast quiescence and its suppression by matrix stiffening amplifies progressive fibrosis.\",\n      \"method\": \"Polyacrylamide gel matrix stiffness manipulation, COX-2 mRNA/protein measurement, PGE2 ELISA, pharmacological rescue with exogenous PGE2/EP2 agonist, proliferation and collagen synthesis assays\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway defined with pharmacological rescue confirming COX-2/PGE2 as central mediator\",\n      \"pmids\": [\"20733059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"A positive feedback loop between PGE2 and COX-2 redirects monocyte differentiation from CD1a+ dendritic cells to CD14+CD33+CD34+ myeloid-derived suppressor cells (MDSCs). Exogenous PGE2 or diverse COX-2 activators (LPS, IL-1β, IFNγ) induce COX-2 expression and endogenous PGE2 production, driving MDSC-associated suppressive factors. Disruption of COX2-PGE2 feedback using COX2 inhibitors or EP2/EP4 antagonists suppresses MDSC function.\",\n      \"method\": \"Monocyte differentiation assays, flow cytometry, pharmacological inhibition (COX2 inhibitors, EP2/EP4 antagonists), ovarian cancer patient samples\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — autocrine feedback mechanism demonstrated with pharmacological dissection and clinical validation in cancer specimens\",\n      \"pmids\": [\"21972293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The non-receptor tyrosine kinase FYN physically interacts with COX-2 (PTGS2) and phosphorylates it at Tyr446; a phospho-mimetic mutation at Tyr446 promotes COX-2 activity, while a phosphorylation-blocking mutation prevents FYN-mediated activity increase, establishing post-translational regulation of COX-2 enzymatic activity by tyrosine phosphorylation independent of changes in protein expression.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis (phospho-mimetic and blocking mutants), COX-2 activity assays in prostate cancer cells\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct phosphorylation demonstrated with mutagenesis confirming functional consequence on enzymatic activity\",\n      \"pmids\": [\"24970799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DNA methylation at the PTGS2 CpG island disrupts CTCF/cohesin complex binding, abrogating chromatin loop formation at the PTGS2 locus and reducing enrichment of positive elongation factor b at the transcriptional start site, thereby downregulating PTGS2 expression. Demethylation restores CTCF/cohesin binding and chromatin looping, re-activating PTGS2 transcription.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), chromatin conformation capture (3C), bisulfite sequencing, demethylation treatment, CTCF/cohesin knockdown\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic epigenetic regulation defined through multiple chromatin biology methods with functional gene expression readout\",\n      \"pmids\": [\"25703332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Ku80 binds the COX-2 (PTGS2) gene promoter and upregulates COX-2 expression in lung cancer cells; the transcriptional co-activator CBP interacts with Ku80 and acetylates it, promoting COX-2 promoter activation. Ku80 knockdown suppresses COX-2 expression, inhibits ERK phosphorylation, and impairs tumor growth in vivo.\",\n      \"method\": \"Streptavidin-agarose promoter pulldown with proteomics, Co-IP, siRNA knockdown, reporter assays, xenograft mouse model\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — promoter binding confirmed by pulldown/proteomics with functional in vivo validation; single lab\",\n      \"pmids\": [\"25797267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The transcription factor ATF3 negatively regulates Ptgs2 expression by binding to the Ptgs2 promoter in activated macrophages. In Atf3-/- mice, peritoneal macrophages show higher Ptgs2 expression and prostaglandin production after zymosan stimulation, and acute peritonitis shows increased leukocyte accumulation and PGE2/PGD2 levels, establishing ATF3 as a transcriptional repressor that terminates Ptgs2 expression during acute inflammation.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), Atf3-/- mouse model, RT-PCR, ELISA for prostaglandins, peritonitis model\",\n      \"journal\": \"Prostaglandins & other lipid mediators\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter binding by ChIP validated in genetic KO model with in vivo inflammatory phenotype\",\n      \"pmids\": [\"25619459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"EPHA2 signaling through TGFβ promotes PTGS2 expression in pancreatic tumor cells; Epha2 or Ptgs2 deletion each reverses T cell exclusion from the tumor microenvironment and sensitizes tumors to immunotherapy, placing PTGS2 downstream of EPHA2-TGFβ in a pathway that drives immunosuppression.\",\n      \"method\": \"Genetic deletion (Epha2-/- and Ptgs2-/- mouse models), pharmacological PTGS2 inhibition, tumor immunophenotyping, immunotherapy response assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis confirmed with two independent KO models and pharmacological validation with defined immune phenotype\",\n      \"pmids\": [\"31162144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Cisplatin induces PTGS2 expression through ROS/NF-κB pathway; PTGS2 then mediates resistance to apoptosis via PGE2/EP4/MAPKs (ERK1/2, P38) axis, upregulating BCL2. Inhibition of PTGS2 by celecoxib augments cisplatin cytotoxicity in resistant gastric cancer cells and xenografts through suppression of PTGS2 and BCL2.\",\n      \"method\": \"Western blotting, ROS measurement, NF-κB pathway inhibitors, PGE2/EP4 axis interrogation, xenograft mouse model, clinical specimen correlation\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — pathway placement by pharmacological dissection with in vivo validation; single lab\",\n      \"pmids\": [\"31518663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Inhibition of mitochondrial oxidative phosphorylation activates AMPK, which stabilizes Ptgs2 mRNA post-transcriptionally in astrocytes, leading to increased COX-2 protein and enhanced eicosanoid secretion (PGE2, PGF2α, 6-keto-PGF1α). AMPK silencing prevents Ptgs2 upregulation by mitochondrial inhibitors, while AMPK activators recapitulate Ptgs2 mRNA stabilization.\",\n      \"method\": \"Mitochondrial inhibitors, AMPK siRNA knockdown, AMPK activators, mRNA stability assay, LC/MS eicosanoid profiling\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — AMPK-dependent mRNA stabilization confirmed by both loss- and gain-of-function; single lab\",\n      \"pmids\": [\"31581537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Macrophage COX-2 is required for efferocytosis (phagocytosis of apoptotic neutrophils) and efferocytosis-dependent macrophage reprogramming. Loss of Cox2 impairs macrophage binding capacity for apoptotic cells, dysregulates polarization, and inhibits production of pro-resolution eicosanoids (PGI2, PGE2, lipoxin A4, 15d-PGJ2). COX2-competent efferocytic macrophages induce intestinal epithelial organoid restitution and repair.\",\n      \"method\": \"Macrophage-specific Cox2 knockout, pharmacological COX2 inhibition, efferocytosis assays with apoptotic neutrophils and synthetic targets, LC-MS/MS eicosanoid lipidomics, intestinal organoid co-culture\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO combined with lipidomic profiling and organoid functional assay with multiple orthogonal methods\",\n      \"pmids\": [\"35017061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"During RAS-induced senescence, COX2 regulates SASP composition through an autocrine feedback loop: COX2-derived PGE2 binds EP4 to modulate expression of multiple inflammatory SASP components including CXCL1. In vivo, Cox2 is required for hepatocyte senescence surveillance, NK/T cell-mediated clearance of senescent cells, and tumor suppression; loss of Cox2 enriches immunosuppressive immature myeloid cells and Treg lymphocytes in the intrahepatic immune microenvironment.\",\n      \"method\": \"RAS-induced senescence model, Cox2 genetic deletion, in vivo hepatocyte senescence model, immune cell profiling, SASP cytokine measurement, PGE2/EP4 pathway pharmacology\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with mechanistic autocrine loop dissection and in vivo immune phenotype; multiple orthogonal methods\",\n      \"pmids\": [\"33730589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The transcription factor CTCF, together with the lncRNA PACERR, recruits the histone acetyltransferase p300 to the promoter regions of PTGS2, enhancing histone acetylation and increasing PTGS2 transcription in tumor-associated macrophages. This CTCF/PACERR/p300 complex promotes M2-like macrophage polarization in pancreatic ductal adenocarcinoma.\",\n      \"method\": \"RNA-seq, ATAC-seq, ChIP-seq, RNA immunoprecipitation, RNA pulldown, CTCF/PACERR knockdown with lentivirus, in vitro and in vivo functional assays\",\n      \"journal\": \"Clinical and translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multi-omics with direct RNA-protein interaction validated by RIP and pulldown; single lab\",\n      \"pmids\": [\"35184402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"DCLK1 kinase binds and phosphorylates XRCC5 (Ku80), which then transcriptionally activates COX-2 (PTGS2) expression and enhances PGE2 production, generating an inflammatory tumor microenvironment that promotes colorectal cancer aggressiveness and stemness.\",\n      \"method\": \"Proteomics, Co-IP, in vitro kinase assay, DCLK1 kinase inhibition in CRC mouse models, gene expression analysis\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct phosphorylation by kinase assay with downstream COX-2 activation validated in mouse models; single lab\",\n      \"pmids\": [\"35910805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Endothelial ROBO4 suppresses PTGS2/COX-2 expression by interacting with IQGAP1 and the ubiquitin E3 ligase TRAF7; ROBO4 enhances TRAF7-mediated ubiquitination of IQGAP1, inhibiting prolonged RAC1 activation and thereby decreasing PTGS2 expression in inflammatory endothelial cells. Robo4-deficient mice show exacerbated PTGS2-associated inflammatory diseases (arthritis, edema, pain).\",\n      \"method\": \"RNA-seq, Co-IP (ROBO4-IQGAP1-TRAF7 interaction), ubiquitination assay, RAC1 activation assay, Robo4-/- mouse model with inflammatory disease phenotyping\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic protein complex defined by Co-IP with ubiquitination assay and validated in KO mouse with disease readout\",\n      \"pmids\": [\"38762541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A small but significant amount of COX-2 protein and mRNA is constitutively expressed in human platelets; the COX1/COX2 mRNA ratio in platelets is ~370:1 and protein ratio ~17:1. COX-2 is also present in platelet-derived microparticles, suggesting a role for platelet COX-2 in physiological and pathological processes including thrombosis.\",\n      \"method\": \"Quantitative RT-PCR, immunostaining, Western blotting of isolated platelets and platelet-derived microparticles\",\n      \"journal\": \"Platelets\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct protein and mRNA detection with quantitative methods; functional role inferred\",\n      \"pmids\": [\"27534811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The transcription factor HIF1α binds to the promoter of Ptgs2 and upregulates its expression; atorvastatin inhibits the HIF1α/Ptgs2 axis, attenuating Ptgs2-mediated ferroptosis and inflammation following coronary microembolization in rats, as confirmed by chromatin immunoprecipitation demonstrating direct HIF1α binding to the Ptgs2 promoter.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), Ptgs2 silencing, rat CME model, ferroptosis marker quantification (MDA, GSH, Fe2+), cardiac function assessment\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrates direct transcription factor-promoter interaction with functional in vivo validation; single lab\",\n      \"pmids\": [\"36569299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Activin A upregulates PTGS2 expression and increases PGE2 production in human granulosa-lutein cells via an ACVR1B-mediated SMAD2/3-SMAD4 signaling pathway, as demonstrated by TGF-β/activin receptor inhibition and SMAD-specific siRNA knockdown.\",\n      \"method\": \"Receptor inhibitor (SB431542), siRNA knockdown of SMADs, PTGS2 mRNA/protein measurement, PGE2 ELISA in primary and immortalized human granulosa-lutein cells\",\n      \"journal\": \"Reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and genetic dissection of signaling pathway with functional PGE2 readout; single lab\",\n      \"pmids\": [\"27624482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LRH-1/NR5A2 regulates PTGS2/COX-2 expression in pancreatic beta cells; LRH-1 ablation blunts Ptgs2 induction by the LRH-1 agonist BL001. Ptgs2 inactivation reduces PGE2 levels and abrogates BL001-mediated islet survival (increased cytochrome c release and cleaved PARP). The PTGER1 receptor antagonist negates BL001-mediated islet survival, defining the LRH-1/PTGS2/PGE2/PTGER1 signaling axis as a beta cell survival pathway.\",\n      \"method\": \"Conditional beta-cell-specific LRH-1 knockout, Ptgs2 inactivation, PGE2 measurement, cytochrome c release and PARP cleavage assays, EP receptor pharmacology\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic pathway defined with conditional KO and pharmacological receptor dissection; single lab\",\n      \"pmids\": [\"35602948\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PTGS2/COX-2 is an inducible prostaglandin endoperoxide H synthase localized to the lumenal face of the ER and nuclear envelope that catalyzes the committed step—conversion of arachidonic acid to PGH2—using both cyclooxygenase and peroxidase activities; its enzymatic output is amplified post-translationally by iNOS-mediated S-nitrosylation and FYN-mediated Tyr446 phosphorylation, and is suppressed at the transcriptional level by ATF3 binding to its promoter, by CTCF/cohesin-mediated chromatin looping (disrupted by DNA methylation), and by the ROBO4-IQGAP1-TRAF7-RAC1 endothelial axis; upstream, PTGS2 is induced downstream of TLR4-MyD88, EPHA2-TGFβ, LRH-1, HIF1α, activin A-SMAD2/3, Gq-calcineurin, and DCLK1-XRCC5 pathways, while aspirin-acetylated COX-2 retains oxygenase activity with altered stereospecificity to generate resolvin precursors; the PGE2 it produces forms autocrine feedback loops that regulate SASP composition during senescence surveillance, redirect monocyte differentiation toward MDSCs, maintain fibroblast quiescence via EP2, and support intestinal epithelial repair and beta-cell survival via PTGER1.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PTGS2 (COX-2) is an inducible prostaglandin-endoperoxide synthase that catalyzes the committed step in prostanoid biosynthesis, converting arachidonic acid to prostaglandin H2, with its products (PGE2, PGI2, TXA2) mediating inflammation, senescence surveillance, efferocytosis, immune modulation, and cell survival through specific EP/TP receptors. PTGS2 transcription is activated by NF-κB, CTCF/cohesin-mediated chromatin looping, HIF1α, LRH-1, activin A–SMAD2/3, and EPHA2–TGFβ signaling, while ATF3 and DNA methylation-dependent disruption of CTCF looping repress it; the lncRNA PACERR recruits p300 to the PTGS2 promoter to enhance histone acetylation, and ROBO4 suppresses PTGS2 via TRAF7-mediated ubiquitination of IQGAP1 and RAC1 inhibition [PMID:8181472, PMID:25703332, PMID:25619459, PMID:35184402, PMID:38762541, PMID:36569299, PMID:27624482, PMID:31162144]. Post-transcriptionally, p38 MAPK and AMPK stabilize PTGS2 mRNA, while FYN phosphorylates COX-2 at Tyr446 to enhance its catalytic activity independently of expression changes [PMID:28192229, PMID:31581537, PMID:24970799]. COX-2-derived PGE2 feeds back through EP4 to amplify COX-2 expression and the senescence-associated secretory phenotype, potentiates macrophage efferocytosis and intestinal epithelial repair, and promotes beta-cell survival through PTGER1, while excessive COX-2 activity drives podocyte injury via thromboxane receptor activation and facilitates tumor immune evasion in pancreatic adenocarcinoma [PMID:33730589, PMID:35017061, PMID:35602948, PMID:19643929, PMID:31162144].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing the genomic identity of the inducible cyclooxygenase resolved that two distinct genes encode constitutive (PTGS1) and inducible (PTGS2) prostaglandin synthase isoforms, with PTGS2 containing NF-κB, CRE, and AP-1 regulatory elements that explain its stimulus-dependent expression.\",\n      \"evidence\": \"PCR cloning, sequencing, FISH mapping of human PTGS2 locus to 1q25.2-q25.3\",\n      \"pmids\": [\"8181472\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional significance of individual promoter elements not tested by mutagenesis\", \"No crystal structure at this stage\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrating that COX-2-derived prostaglandins (PGE2, 15d-PGJ2) upregulate COX-2 itself established a positive autocrine feedback loop, explaining how transient stimuli can produce sustained prostanoid production.\",\n      \"evidence\": \"PG metabolite treatment of mouse lung fibroblasts with RT-PCR and Western blot readouts\",\n      \"pmids\": [\"15883739\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating the feedback not identified in this study\", \"In vivo relevance not demonstrated\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Linking Gq-calcineurin/NFAT signaling to COX-2 induction in podocytes, with COX-2 inhibition rescuing injury, established that excessive COX-2-derived prostaglandins mediate glomerular pathology downstream of G-protein-coupled receptor activation.\",\n      \"evidence\": \"TAT-protein transduction of constitutively active Gqα in podocytes and transgenic mouse model with COX-2 inhibitor treatment\",\n      \"pmids\": [\"18667730\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific prostanoid receptor mediating injury not fully resolved here\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Genetic dissection using COX-2-overexpressing and TP-receptor-knockout mice revealed that COX-2 overexpression sensitizes podocytes to injury specifically through thromboxane receptor signaling, while basal COX-2 is protective, resolving the dual role of COX-2 in kidney.\",\n      \"evidence\": \"Transgenic COX-2 overexpression crossed with conditional TP-receptor knockout, albuminuria and podocyte morphology\",\n      \"pmids\": [\"19643929\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which basal COX-2 is protective not defined\", \"Downstream intracellular signaling from TP not mapped\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of FYN-mediated Tyr446 phosphorylation as a post-translational activator of COX-2 enzyme activity revealed a regulatory layer independent of transcriptional or mRNA control, explaining how COX-2 output can be modulated without changes in protein abundance.\",\n      \"evidence\": \"In vitro kinase assay, Co-IP, site-directed mutagenesis with prostaglandin activity measurement\",\n      \"pmids\": [\"24970799\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological contexts in which FYN-COX-2 axis operates in vivo not defined\", \"Whether other Src-family kinases phosphorylate the same site is unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Discovery that ATF3 directly binds the PTGS2 promoter to repress transcription, and that DNA methylation disrupts CTCF/cohesin chromatin looping required for transcriptional elongation, established dual negative regulatory mechanisms at the epigenetic and transcription-factor levels.\",\n      \"evidence\": \"ChIP in Atf3-knockout macrophages; chromatin conformation capture and methylation analysis in cancer cell lines\",\n      \"pmids\": [\"25619459\", \"25703332\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ATF3 and CTCF/methylation mechanisms interact at the same locus is untested\", \"Signals that remove ATF3 from the promoter during sustained induction not characterized\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identification of Ku80 (XRCC5) as a PTGS2 promoter-binding transactivator acetylated by CBP, and later shown to be phosphorylated by DCLK1, revealed a signaling cascade (DCLK1→XRCC5→COX-2) linking DNA repair proteins to inflammatory gene expression in cancer.\",\n      \"evidence\": \"Streptavidin pulldown with proteomics and Co-IP in lung cancer cells; DCLK1 kinase assay and CRC mouse models\",\n      \"pmids\": [\"25797267\", \"35910805\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Ku80-mediated COX-2 regulation occurs outside cancer contexts is unknown\", \"Direct DCLK1 phosphorylation site on Ku80 not fully mapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showing that HNE and oxidized LDL induce COX-2 through p38 MAPK-dependent mRNA stabilization, and that AMPK activation independently stabilizes PTGS2 mRNA, established post-transcriptional mRNA stability as a major regulatory tier for COX-2 expression under metabolic and oxidative stress.\",\n      \"evidence\": \"mRNA decay assays with p38/AMPK inhibition and siRNA in cell-based models\",\n      \"pmids\": [\"28192229\", \"31581537\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"RNA-binding proteins mediating the stabilization not identified\", \"Whether p38 and AMPK act on the same AU-rich elements is untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Genetic epistasis showing that EPHA2-driven PTGS2 expression excludes T cells from pancreatic tumors, with Ptgs2 deletion phenocopying Epha2 deletion in restoring immunotherapy sensitivity, placed COX-2 as a central effector of tumor immune evasion.\",\n      \"evidence\": \"Epha2 and Ptgs2 single/double knockout mouse pancreatic cancer models with immune phenotyping\",\n      \"pmids\": [\"31162144\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which COX-2-derived prostanoid and receptor on T cells mediates exclusion not resolved\", \"Applicability beyond pancreatic cancer unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstration that COX-2/PGE2 signals through EP4→ERK/p38→BCL2 to confer cisplatin resistance, and that COX-2 activates NF-κB to suppress DNA damage response after radiation, revealed COX-2 as a convergent mediator of therapy resistance through both anti-apoptotic and DNA-damage-evasion mechanisms.\",\n      \"evidence\": \"siRNA/overexpression with pathway inhibitors in gastric cancer xenografts and glioma clonogenic assays\",\n      \"pmids\": [\"31518663\", \"30740906\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether COX-2-mediated resistance generalizes across tumor types needs systematic testing\", \"Direct NF-κB targets downstream of COX-2 in radioresistance not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identifying COX-2 as a master regulator of the senescence-associated secretory phenotype via PGE2-EP4 autocrine feedback, required for immune-mediated senescence surveillance and tumor suppression in vivo, unified COX-2's roles in inflammation and tumor suppression.\",\n      \"evidence\": \"Cox2 knockout in RAS-induced senescence models with in vivo hepatic surveillance and immune cell profiling\",\n      \"pmids\": [\"33730589\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether COX-2's SASP role is context-dependent (oncogene-specific) is unresolved\", \"Downstream signaling from EP4 to specific SASP factor transcription not fully mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Multiple 2022 studies converged to define tissue-specific transcriptional regulators and downstream functions: CTCF/PACERR/p300 drives PTGS2 in tumor-associated macrophages; LRH-1 drives PTGS2/PGE2/PTGER1 for beta-cell survival; HIF1α drives PTGS2 in ferroptosis; ROBO4 suppresses PTGS2 via TRAF7-mediated IQGAP1 ubiquitination; and macrophage COX-2 potentiates efferocytosis and epithelial repair.\",\n      \"evidence\": \"ChIP-seq/ATAC-seq/RNA-ChIP for PACERR; beta-cell-specific LRH-1 KO mice; Ptgs2 ChIP for HIF1α; Robo4 KO mice with arthritis models; macrophage-specific Cox2 KO with organoid co-culture and lipidomics\",\n      \"pmids\": [\"35184402\", \"35602948\", \"36569299\", \"38762541\", \"35017061\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Integration of multiple transcriptional inputs at a single PTGS2 locus in a given cell type remains unmodeled\", \"Whether ROBO4-TRAF7-IQGAP1 axis operates outside endothelial cells is unknown\", \"Structural basis for PACERR-CTCF interaction not determined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the cell integrates the many transcriptional, post-transcriptional, and post-translational inputs to set context-appropriate COX-2 output — and what determines whether COX-2-derived prostanoids promote tumor suppression (senescence surveillance) versus tumor immune evasion — remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No systems-level model integrating all regulatory inputs at the PTGS2 locus\", \"Structural basis for FYN selectivity at Tyr446 and its interplay with other kinases unknown\", \"Whether COX-2's pro- versus anti-tumorigenic roles are determined by prostanoid receptor expression patterns in the microenvironment has not been systematically tested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1, 8]},\n      {\"term_id\": \"GO:0009975\", \"supporting_discovery_ids\": [0, 8, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 8, 13]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 7, 11, 12, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [11, 13, 16]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [9, 17, 21]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 3, 4, 16, 22]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"FYN\",\n      \"ATF3\",\n      \"CTCF\",\n      \"XRCC5\",\n      \"IQGAP1\",\n      \"TRAF7\",\n      \"NR5A2\",\n      \"EPHA2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"PTGS2 (COX-2) is an inducible bifunctional enzyme that catalyzes the committed step in prostanoid biosynthesis—converting arachidonic acid to PGH2 via sequential cyclooxygenase and peroxidase activities—and resides on the lumenal face of the endoplasmic reticulum and nuclear envelope [PMID:1380156, PMID:7947975, PMID:9545330]. Transcriptional induction is driven by NF-κB, HIF1α, LRH-1, SMAD2/3, and CTCF/cohesin-dependent chromatin looping, while ATF3 acts as a transcriptional repressor; post-transcriptionally, miR-16 promotes ARE-mediated mRNA decay and AMPK stabilizes PTGS2 mRNA [PMID:25619459, PMID:25703332, PMID:15766526, PMID:31581537]. Enzymatic output is amplified by iNOS-mediated S-nitrosylation and FYN-dependent Tyr446 phosphorylation, and aspirin acetylation redirects oxygenase stereospecificity to generate pro-resolution resolvin precursors from DHA [PMID:16373578, PMID:24970799, PMID:12391014]. The PGE2 produced by PTGS2 drives diverse tissue-specific programs including intestinal epithelial repair downstream of TLR4, senescence surveillance via autocrine EP4 signaling, monocyte-to-MDSC differentiation, brown adipocyte recruitment in white fat, macrophage efferocytosis, and tumor immune evasion downstream of EPHA2-TGFβ [PMID:16952555, PMID:33730589, PMID:21972293, PMID:20448152, PMID:35017061, PMID:31162144].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Cloning of human PTGS2 from endothelial cells and demonstration of cyclooxygenase activity in heterologous cells established it as a second, inducible prostaglandin H synthase isoform distinct from COX-1, answering whether a separate inducible cyclooxygenase gene exists in humans.\",\n      \"evidence\": \"Molecular cloning from HUVECs with functional expression in COS-7 cells; independently replicated with chromosomal mapping to 1q25\",\n      \"pmids\": [\"1380156\", \"8473346\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure of human COX-2 not yet solved at this time\", \"Substrate specificity differences versus COX-1 not yet characterized\", \"In vivo physiological roles undefined\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Determination of the PTGS2 gene structure revealed ARE-rich 3'-UTR elements and NF-κB/CRE promoter sites, explaining how COX-2 is both transcriptionally induced and post-transcriptionally labile; concurrent biochemical characterization of recombinant enzyme confirmed dual cyclooxygenase and peroxidase activities with self-inactivation kinetics.\",\n      \"evidence\": \"Genomic sequencing with FISH mapping; baculovirus-expressed purified enzyme with kinetic analysis\",\n      \"pmids\": [\"8181472\", \"7945196\", \"7947975\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of trans-acting factors for ARE-mediated decay unknown\", \"Structural basis for NSAID selectivity not resolved\", \"Post-translational regulatory mechanisms uncharacterized\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Immunoelectron microscopy resolved the long-standing question of whether COX-1 and COX-2 occupy distinct compartments: both localize to the ER and nuclear envelope lumen, indicating their functional independence arises from differential expression rather than compartmentalization.\",\n      \"evidence\": \"Immunogold EM across monocytes, NIH 3T3, and HUVECs with subcellular fractionation and isozyme-selective inhibitor controls\",\n      \"pmids\": [\"9545330\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of preferential coupling to specific downstream synthases despite shared localization unclear\", \"Whether nuclear envelope localization has distinct functional consequences unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstration that COX-2-overexpressing tumor cells stimulate angiogenesis through prostaglandin production established COX-2 as a pro-tumorigenic enzyme, shifting the field beyond inflammation to cancer biology.\",\n      \"evidence\": \"Coculture angiogenesis assays with COX-2 overexpression and NS-398 inhibition in colon carcinoma and endothelial cells\",\n      \"pmids\": [\"9630216\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific prostaglandin species mediating angiogenesis not fully defined\", \"In vivo relevance to spontaneous tumor angiogenesis not yet shown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Discovery that aspirin-acetylated COX-2 retains oxygenase activity but with altered stereospecificity to produce 17R-HDHA (resolvin precursor) from DHA revealed an unexpected gain-of-function mechanism, redefining aspirin's anti-inflammatory action beyond simple enzyme inhibition.\",\n      \"evidence\": \"LC-MS lipidomic analysis of aspirin-treated recombinant COX-2 with cell-based validation in microglia and endothelial cells\",\n      \"pmids\": [\"12391014\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of aspirin-triggered resolvins to clinical anti-inflammatory effects not established\", \"Whether other COX-2 covalent modifications similarly redirect stereospecificity unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Two post-transcriptional and post-translational control layers were defined: miR-16 cooperates with tristetraprolin to degrade COX-2 mRNA via its ARE, and iNOS physically binds and S-nitrosylates COX-2 to enhance its catalytic activity, establishing that COX-2 output is regulated beyond transcription.\",\n      \"evidence\": \"miR-16 RNAi screen in Drosophila S2 validated in HeLa; iNOS–COX-2 Co-IP with S-nitrosylation assay and interaction disruption\",\n      \"pmids\": [\"15766526\", \"16373578\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"S-nitrosylation site(s) on COX-2 not mapped\", \"Whether miR-16 and S-nitrosylation operate simultaneously in the same cell types unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Genetic studies in TLR4-deficient mice placed PTGS2-derived PGE2 downstream of TLR4-MyD88 in intestinal epithelial repair, explaining how innate immune sensing drives mucosal homeostasis through prostanoid production.\",\n      \"evidence\": \"TLR4−/− mice with DSS colitis, MyD88 siRNA, BrdU/TUNEL assays, PGE2 rescue\",\n      \"pmids\": [\"16952555\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"EP receptor subtype mediating intestinal repair downstream of TLR4 not fully defined\", \"Whether epithelial or stromal COX-2 is the principal source not resolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"COX-2 was identified as an effector of β-adrenergic signaling that drives brown adipocyte recruitment in white fat depots, and separately as a mechanoresponsive gene whose suppression by matrix stiffening removes the PGE2/EP2 brake on fibroblast activation, broadening COX-2 biology to metabolism and fibrosis.\",\n      \"evidence\": \"WAT-specific Cox-2 transgenic and knockout mice with metabolic phenotyping; tunable-stiffness polyacrylamide gels with PGE2/EP2 rescue in fibroblasts\",\n      \"pmids\": [\"20448152\", \"20733059\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the prostaglandin species mediating brown fat induction not fully resolved\", \"In vivo relevance of matrix-stiffness–COX-2 axis in human fibrotic disease not confirmed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"A COX-2/PGE2 autocrine feedback loop was shown to redirect monocyte differentiation toward immunosuppressive MDSCs via EP2/EP4, providing a mechanistic link between tumor-derived COX-2 activity and immune evasion.\",\n      \"evidence\": \"Monocyte differentiation assays with COX-2 inhibitors and EP2/EP4 antagonists; validated in ovarian cancer patient specimens\",\n      \"pmids\": [\"21972293\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this loop operates in all tumor types or is context-specific unclear\", \"Downstream transcriptional program in MDSCs not fully mapped\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"FYN-mediated phosphorylation of COX-2 at Tyr446 was identified as a post-translational activating modification, establishing that kinase signaling directly modulates COX-2 enzymatic output independent of expression changes.\",\n      \"evidence\": \"Co-IP, in vitro kinase assay, phospho-mimetic and blocking mutants in prostate cancer cells\",\n      \"pmids\": [\"24970799\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Tyr446 phosphorylation occurs in non-cancer contexts unknown\", \"Phosphatase(s) that reverse this modification not identified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Epigenetic and transcriptional silencing mechanisms were defined: DNA methylation at the PTGS2 CpG island disrupts CTCF/cohesin-mediated chromatin looping, while ATF3 directly represses the Ptgs2 promoter during inflammation resolution, establishing how PTGS2 is turned off.\",\n      \"evidence\": \"ChIP, 3C chromatin conformation capture, bisulfite sequencing, demethylation; Atf3−/− mice with peritonitis model and ChIP\",\n      \"pmids\": [\"25703332\", \"25619459\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CTCF/cohesin and ATF3 mechanisms operate sequentially or independently unresolved\", \"Writers responsible for PTGS2 CpG island methylation not identified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"EPHA2-TGFβ signaling was placed upstream of PTGS2 in pancreatic cancer immune evasion, and AMPK-dependent mRNA stabilization was identified as a metabolic stress–responsive post-transcriptional mechanism, further expanding the repertoire of PTGS2 induction pathways.\",\n      \"evidence\": \"Epha2−/− and Ptgs2−/− mouse tumor models with immunotherapy; AMPK siRNA and activators with mRNA stability assays in astrocytes\",\n      \"pmids\": [\"31162144\", \"31581537\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"AMPK-dependent stabilization mechanism (RNA-binding protein intermediary) not identified\", \"Whether EPHA2-PTGS2 axis is specific to pancreatic cancer or generalizable unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"COX-2 was shown to be essential for macrophage efferocytosis and subsequent pro-resolution reprogramming, and for shaping SASP composition during senescence surveillance via PGE2/EP4 autocrine signaling, revealing COX-2 as a gatekeeper of immune resolution programs.\",\n      \"evidence\": \"Macrophage-specific Cox2 KO with efferocytosis assays and LC-MS/MS lipidomics; RAS-induced senescence with Cox2 deletion and in vivo hepatocyte surveillance model\",\n      \"pmids\": [\"35017061\", \"33730589\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which COX-2 loss impairs apoptotic cell binding not defined\", \"Whether senescence surveillance role extends beyond hepatocytes unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Multiple transcriptional activators of PTGS2 were further defined: CTCF/PACERR/p300 complex in tumor-associated macrophages, DCLK1-phosphorylated Ku80 in colorectal cancer, HIF1α direct promoter binding in cardiac ischemia, and LRH-1 in beta cells, revealing tissue-specific transcriptional wiring converging on PTGS2.\",\n      \"evidence\": \"ChIP-seq, RNA pulldown, RIP for CTCF/PACERR; DCLK1 kinase assay with Co-IP; HIF1α ChIP in rat CME model; conditional beta-cell LRH-1 KO with EP receptor pharmacology\",\n      \"pmids\": [\"35184402\", \"35910805\", \"36569299\", \"35602948\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PACERR lncRNA is required or modulatory for PTGS2 induction needs independent replication\", \"DCLK1-Ku80-COX-2 axis demonstrated in single lab\", \"HIF1α-PTGS2-ferroptosis link requires human validation\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"An endothelial-specific suppressive pathway was delineated: ROBO4 recruits TRAF7 to ubiquitinate IQGAP1, preventing sustained RAC1 activation and thereby suppressing PTGS2 expression, with Robo4-deficient mice exhibiting exacerbated inflammatory disease.\",\n      \"evidence\": \"Co-IP of ROBO4-IQGAP1-TRAF7, ubiquitination assay, RAC1 activation assay, Robo4−/− mice with arthritis/edema/pain models\",\n      \"pmids\": [\"38762541\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ROBO4-TRAF7 axis operates in non-endothelial cell types unknown\", \"Direct ligand triggering ROBO4 to suppress COX-2 not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Unresolved questions include: the structural basis for how S-nitrosylation and Tyr446 phosphorylation individually and combinatorially alter COX-2 catalytic geometry; the mechanism by which COX-2 preferentially couples to mPGES-1 despite shared ER localization with COX-1; and whether COX-2's roles in efferocytosis, senescence surveillance, and brown fat recruitment depend on the same or distinct prostaglandin products.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal structure of S-nitrosylated or Tyr446-phosphorylated COX-2\", \"Prostaglandin species specificity for individual tissue-level functions not resolved\", \"Mechanistic basis for preferential COX-2–mPGES-1 coupling still debated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1, 3, 8]},\n      {\"term_id\": \"GO:0009975\", \"supporting_discovery_ids\": [0, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0005635\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 3, 8, 10, 15]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 13, 17, 22, 25, 26]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [13, 16, 22, 29, 32, 33]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [6, 14, 22, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"NOS2\",\n      \"FYN\",\n      \"ATF3\",\n      \"CTCF\",\n      \"XRCC5\",\n      \"IQGAP1\",\n      \"TRAF7\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}